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Chapter 1: Introduction 
The primary goal of this research was to understand the mechanism of 
milk-lipid secretion in the lactating mammary gland at the cellular and 
molecular level. In this introductory section, the mammary gland system will 
be reviewed, especially with regard to gland structure, and the synthesis and 
secretion of milk constituents.  
 
1. 1. Mammary gland and formation of milk 
The mammary gland is a defining characteristic of mammals that 
undergoes terminal differentiation during pregnancy and lactation, and that 
provides the neonate with essential nutrients in the form of milk during 
lactation (1). Development of the gland begins at embryonic day 13 in the 
mouse, and following birth, it continues through puberty. During puberty, 
growth and development of mammary gland is influenced by changes in the 
hormonal environment, which accompany the onset of ovarian cycling in 
females. The mammary gland increases in size, and the ducts extend into a 
glandular fat pad, but no secretory epithelium is evident. (Fig. 1.1 a). During 
pregnancy, the gland undergoes rapid development, and an extensive 
ductular tree is formed within lobular-alveolar structures (1) (Fig. 1.1 b). 
Progesterone from the ovaries and prolactin from the pituitary are essential 
for side branching and alveolar formation (2). During transition from the end of 
pregnancy (day 21) to the lactating phase in the mouse, the gland begins to 
secrete large amounts of milk. The lactating gland consists of a branched  




Fig. 1.1. Mouse mammary gland development. (a) At the onset puberty, the 
mammary gland increases in size, and the ducts penetrate into a glandular fat 
pad. (b) During pregnancy, alveolar and ductal epithelial cells proliferate and 
differentiate, and lobulo-alveolar structures are formed. (c) The lactating gland 
consists of extensive lobulo-alveolar clusters and secretes milk. (d) Involution 
returns the ductal structure to the non-pregnant state. Figure is from the 
website: http://mammary.nih.gov/atlas. 
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ductular network which is formed of epithelial cells ending in extensive lobulo-
alveolar clusters (Fig 1.1 c) (1). Each alveolus is lined by polarized secretory 
epithelial cells and myoepithelial cells facing a central lumen (1) (Fig. 1.2 a). 
Milk is secreted from the secretory epithelial cell. The function of 
myoepithelial cells is to eject milk from the alveolar luminae following 
oxytocin-induced contraction during milk ‘let-down’ (Fig.1.2 a) (7). Following 
lactation, the mammary gland undergoes massive remodeling and the 
secretory cells undergo apoptosis, which results in involution of the mammary 
gland (Fig. 1.1 d). 
 
Milk consists of essential constituents for neonatal survival including 
proteins, lipid [triacylglycerols (TAGs)], carbohydrate (lactose), ions (K+, Na+, 
Cl-, and Ca2+), water, immunoglobulins (IgG, slgA, and sIgM), and cells 
(macrophages). The majority of protein in milk comprises the caseins, which 
are transported to the Golgi apparatus, packaged into secretory vesicles, and 
secreted into milk by exocytosis (6) (Fig. 1.2 b, mechanism E). However, milk-
lipid is secreted by an entirely different mechanism, which is unique to the 
mammary gland. Synthesized lipid droplets from the endoplasmic reticulum 
(ER) are transported through the cytoplasm to the apex of the cell and 
enveloped with a layer of the apical plasma membrane (6) (Fig. 1.2 b, 
pathways I and II). Potential mechanisms for milk-lipid secretion will be 
discussed later. Milk constituents such as immunoglobulins, ions, and other 
proteins such as transferrin and prolactin are transported by transcytosis.  
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Fig. 1.2. Mammary gland. (a) The milk-secreting alveolus with a basket of 
contractile myoepithelial cells (green). Figure taken from reference (3). (b) 
Pathways for lipid droplet transit and secretion. MLDs (micro lipid droplets) 
formed in the ER fuse with each other and with larger CLDs. They are 
transported through cytoplasm to the apical plasma membrane, surrounded 
by the bilayer of the apical membrane (mechanism B), and secreted into the 
lumen (Pathway I). MLDs can be directly transported to the apex of the cell 
(Pathway II), surrounded by the apical membrane, and secreted into the 
lumen (mechanism A). Golgi-derived secretory vesicles surround lipid 
droplets, and fuse with each other to form vacuole-like structures. 
Subsequently, such vacuole-like structures fuse with the apical plasma 
membrane, and the lipid droplets are released from the cells by exocytosis 
(mechanism C and D) (4, 5). Caseins and other skim-milk proteins are 
secreted by exocytosis (mechanism E). Apical plasma membrane (APM); 
basal plasma membrane (BPM); cytoplasmic lipid droplet (CLD); casein 
micelle (CM); cytoplasmic crescent (CR); rough endoplasmic reticulum (rER); 
lipid droplet (LD); Golgi apparatus (GA); microlipid droplet (MLD); nucleus (N); 
secretory vesicle (SV) Figure taken from reference (6). 
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They are internalized from the basolateral membrane, sorted in endosomes, 
and transported to the apical plasma membrane either through specific 
vesicles or possibly from secretory vesicles formed in the Golgi apparatus (8, 
9). 
 
1. 2. Origin and formation of lipid droplets 
The major lipids in milk are TAGs which comprise about 98% of the total. 
That the precursors of lipid droplets are formed in the ER (1, 10) is based on 
several lines of experimental evidence. Firstly, the activities of several 
acyltransferases, which esterify fatty acids in the sn- 1 and 2 positions of 
glycerol-3-phosphate were enriched in microsomal fractions from lactating rat 
mammary gland (11). Secondly, electron microscope radioautograpy showed 
that 95% of the radiolabeled fatty acids injected into rats was rapidly esterified 
into TAGs and that the radioautographic reactions were localized to the ER 
within 1 min after injection (12). No radioactivity was seen in the Golgi 
apparatus indicating that the formation of lipid droplets is different from the 
formation and secretion of casein micelles from Golgi-derived secretory 
vesicles (12). Interestingly, esterified fatty acids rapidly associated with visible 
lipid droplets suggesting either that newly synthesized TAGs rapidly associate 
with pre-existing lipid droplets, or that the formation of lipid droplets is very 
quick (12). Thirdly, in terms of phospholipid composition, surface coat 
materials on cytoplasmic lipid droplets (CLDs) resemble the phospholipid 
composition of the ER (13). Fourthly, rabbit antibody prepared against CLDs 
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binds to the ER as well as the surface of CLDs and micro-lipid droplets 
(MLDs) (precursors of CLDs, with diameters less than 0.5 µm), which 
suggests that the ER, MLDs, and CLDs share a number of common 
polypeptides, and that the formation of lipid droplets occurs in the ER (14). 
However, the purity of the CLD fraction used to immunize the rabbits, and 
specificity of the resulting antibody have been questioned. (13, 14). More 
convincingly, isolated MLDs from rat mammary gland have abundant ER 
resident proteins, such as protein disulfide isomerase, calreticulin, and 
immunoglobulin binding protein (Bip, GRP 78), which strongly suggests that 
precursors of lipid droplets are formed in the ER (15). Although the exit site of 
nascent droplets from the ER is controversial, the current consensus is that 
TAGs initially accumulate between the inner and outer bilayer halves of the 
ER membrane (16). This mechanism is based on the use of osmium tetroxide 
as a lipid stain and fixative, which highlights presumptive foci of lipid bilayer 
between the outer and inner halves of the ER, which are distinct from the 
staining characteristics of CLDs in the cytoplasm (17).  
 
CLDs grow to more than 4 µm in diameter by the progressive fusion of 
MLDs (13, 14). In a cell-free system, fusion of MLDs, following release of lipid 
from the ER, required calcium ions at an optimal concentration of 2.5 mM and 
a protein complex from the cytosol (18). In addition, an exogenous supply of 
gangliosides enhanced fusion (18). The active protein fraction from the 
cytosol may be an aggregate or a complex comprising multi-subunit proteins, 
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because fusion of MLDs occurred with a protein fraction of more than 200 
kDa prepared by gel permeation chromatography (18). This fraction 
comprised four polypeptides with molecular masses in a range between 15 – 
20 kDa (18).  
 
Fusion of MLDs is one possible mechanism to explain an increase in the 
volume of lipid droplets. However, there are other possibilities. For example, 
4% or more of total neutral lipids and phospholipids are found in cytosolic 
fractions and much of these are associated with the fatty acid synthetase 
complex, which suggests that MLDs may acquire neutral lipids and 
phospholipids directly from the cytoplasm to form CLDs (19, 20). Interestingly, 
a group of GTP-binding proteins are found in the fatty acid synthase complex 
which suggests that GTP-binding proteins may function in the intracellular 
transit of lipid droplets (20). In addition, bovine fatty acid synthetase complex 
may contain butyrophilin 1a1, and xanthine oxidoreductase (two major 
proteins in the milk fat globule membrane (MFGM)) (20), but this observation 
does not agree with more recent immunohistochemical data on the 
intracellular distribution of these proteins (21-23). 
 
1. 3. Intracellular trafficking of lipid droplets 
As discussed above, lipid droplets are formed in the ER, and migrate 
from the ER to the apical plasma membrane, bypassing the Golgi apparatus. 
However, the mode of transit through the cell is unclear.  
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Microtubules are present in all mammary secretory cells, especially in the 
apical and medial cytoplasm in contact with small vesicles from 50 to 150 nm 
in diameter (24). Most of these microtubules are oriented perpendicularly to 
the apical plasma membrane, which suggests that they have important roles 
in guiding secretory vesicles and possibly lipid droplets toward the cell apex 
(25). Interestingly, when microtubule assembly was reversibly inhibited by the 
infusion of the plant alkaloids, colchicine and vincristine, into lactating goat 
mammary glands, both the synthesis and secretion of milk were inhibited (26). 
In another study, the milk fat content increased 36 – 48 hour after colchicine 
infusion into lactating goat mammary glands, and the diameter of the lipid 
droplets within the lactating cells was doubled, which suggests that colchicine 
does not inhibit the synthesis of milk-lipid per se, but milk-lipid secretion, such 
that large lipid droplets accumulate in the cells, until the effect of the inhibitor 
wears off (27). At this point, the accumulated lipid droplet is secreted in a 
wave; thus accounting for the transient rise in milk fat content and globule 
size following infusion (28). However, in other studies, the concentration of fat 
was not significantly affected by colchicine treatment, and treatment of 
colchicine in lactating goat mammary glands reduced the extraction of 
essential and non-essential amino acids, which are required for the synthesis 
of milk proteins (29). The drop in amino acid uptake paralleled the fall in milk 
protein yield, suggesting that colchicine may secondarily affect lipid secretion 
by affecting nutrient uptake or general cell metabolism (29). In addition, 
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incubation of mammary tissue fragments from lactating ewes and rabbits with 
colchicine did not inhibit lipid secretion, and after the immediate addition of 
prolactin, lipid secretion significantly increased suggesting that microtubule 
integrity is not required for lipid secretion (30). Incubation of lactating rat 
mammary explants with colchicine, in vitro, caused the accumulation of 
casein-containing secretory vesicles in the cytoplasm. However, there was 
little accumulation of lipid droplets. Thus, colchicine effects appear to be 
greater in vivo than in vitro. In summary, because of different observations 
and discrepancies between different studies, it is not clear what specific role 
microtubules may play in milk-lipid secretion.  
 
With regard to microfilaments, skeletal muscle actin (42 kDa), clathrin, 
and cortactin-binding protein 1 (CortBP1) (180 kDa) are more abundant in 
alveolar milk-secreting cells than in contractile myoepithelial cells (31, 32). 
Treatment of lactating guinea pig mammary gland with cytochalasin B, a 
microfilament-altering drug, either inhibits lactose synthesis in the Golgi 
apparatus or secretion from the apical plasma membrane (33), suggesting 
that microfilaments are involved in the classical secretory pathway in lactation. 
Even though actin filaments can be identified with specific antibodies in apical 
regions of epithelial cells, they have not been detected on the surface of lipid 
globules and luminal areas of budding lipid droplets by immunofluorescence 
microscopy, which suggests that microfilaments may not function in lipid 
secretion (34). However, recent proteomic analysis of human MFGM has 
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shown that actin and actin-binding proteins are bound to the MFGM as well 
as the small GTP-binding protein RhoA, which is essential for secretory 
function and actin remodeling (35). Thus, the functional role of microfilaments 
in milk-lipid secretion is still not clear.  
 
1. 4. Secretion of lipid droplets 
As discussed in Fig. 1.2, the generally accepted mechanism for lipid 
droplet secretion in lactating mammary gland is that lipid droplets move 
directly toward the cell apex, and are surrounded by the apical plasma 
membrane, as they are released from the cell into the lumen (6, 34) (Fig. 1.2, 
mechanisms A and B). In an alternative mechanism, Wooding has proposed 
that Golgi-derived secretory vesicles containing casein micelles surround lipid 
droplets in the apex of the cell, and fuse with each other to form vacuole-like 
structures, which surround the lipid droplets. Subsequently, such vacuole-like 
structures fuse with the apical plasma membrane, and the lipid droplets are 
released from the cells by exocytosis (4, 5) (Fig. 1.2, mechanism C and D).  
 
Most histochemical data support the apical route (34). Butyrophilin 1A1 
(BTN1) is one of the major MFGM proteins, and is concentrated in the apical 
plasma membrane, not in secretory vesicles, the Golgi apparatus or the ER 
(34). The mucin, MUC1, is also concentrated in the apical plasma membrane 
                                            
1 Butyrophilin will be denoted as BTN for cow and human butyrophilin 1A1, and also for 
mouse butyrophilin 1a1. 
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and MFGM (22, 36). According to quantitative immunocytochemistry, analysis 
of guinea pig epithelial cells, the concentration of MUC1 on the apical plasma 
membrane and MFGM was approx. ten fold higher than on secretory vesicle 
membrane (36). The ratio of MUC1 on the apical plasma membrane to MUC1 
on basal/lateral membranes was 99:1 (36). These data strongly suggest that 
milk-lipid droplets are directly enveloped by the apical plasma membrane 
rather than Golgi-derived secretory vesicles during secretion (4, 5).  
 
The outer layer of the MFGM is directly derived from the apical plasma 
membrane (6) (Fig. 1.3 a). In electron micrographs, one face of isolated 
MFGM displays a membrane-like structure, but the other side of the 
membrane is coated with a thick layer of bound materials (37). In addition, in 
the process of secretion, the lipid droplet remains a constant distance of 
about 10-20 nm from the outer apical membrane bilayer (56). This layer is 
composed of proteins, and appears as a fuzzy electron dense coat in electron 
micrographs of isolated membrane (39, 40) (Fig. 1.3 c). Electron microscopy 
has shown that areas of the protein coat appear as a highly ordered 
paracrystalline structure with hexagonal symmetry in freeze-etched 
preparations (41) (Fig. 1.3 b), which suggests that integral and cytosolic 
proteins, resident in the apical plasma membrane, are recruited into highly 
ordered complexes.  
 
1. 5. MFGM proteins and their potential role in lipid droplet trafficking  






Fig. 1.3. Electron microscopy of lipid secretion and MFGM formation. (a) 
Budding lipid droplet from the apical surface of secretory cell (Mather, I. H., 
unpublished data). (b) Freeze-etch microscopy of inner surface of MFGM (41). 
(c) Electron micrograph of MFGM. Black arrowhead, dense coat on inner face 
of membrane (39).  
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and milk-lipid secretion 
The protein composition of the MFGM has been the subject of intensive 
study (6), especially to identify proteins that may function in either lipid droplet 
trafficking or secretion. Several proteins were identified that are associated 
with both intracellular lipid droplets and the MFGM (42). As noted above, 
proteomics analysis has shown that ER resident proteins are found in both 
intracellular lipid droplets as well as the MFGM, which suggests either that 
these proteins are involved in transition from MLDs to CLDs or that they 
function in trafficking lipid droplets to the apical plasma membrane (42). In 
addition, cytoskeletal proteins were also found in intracellular lipid droplets 
suggesting that they may function in the transit of CLDs to the apical plasma 
membrane (42). The mechanisms involved in the release and scission of lipid 
droplets are not clear. Protein kinases, such as trimeric G protein β−subunit, 
may function in the secretion of lipid droplets, because the β−subunit of 
trimeric G proteins is enriched in MFGM, but not in CLDs (42). In addition, 
even though trimeric G protein is known generally as a modulator or 
transducer in transmembrane signaling systems, it is also involved in the 
calcium dependent exocytosis of secretory vesicles in pancreatic beta cells 
(42).  
  
Several major MFGM proteins may play pivotal roles in the secretion of 
lipid droplets. Major proteins in bovine MFGM are the mucins MUC1 and 
MUC15, the redox enzyme, xanthine oxidoreductase (XOR), cluster of 
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differentiation 36 (CD36), BTN, adipophilin (ADPH), periodic acid Schiff 
glycoprotein 6/7 (PAS6/7), and fatty acid binding protein (FABP) (43) (Fig. 
1.4).  
 
MUC1 mucins have a type 1 orientation, and the exoplasmic domain is highly 
glycosylated (43). Depending upon species, they contain multiple tandem 
repeats, and short cytoplasmic tails (43). MUC1 is expressed in most simple 
secretory epithelial cells, and may protect the cell surface from physical 
damage and invasion by microorganisms (44). However, MUC1 deficient mice 
are healthy and fertile, and lactation appears to be normal, suggesting that 
MUC1 is not essential in the mechanism of milk secretion (44). MUC15 
(formerly called PAS III) is a type 1 transmembrane protein, and like MUC1, 
has structural hallmarks of mucins such as a high content of serine, threonine, 
and proline and large quantities of carbohydrate (45, 46). The extracellular 
region has 11-15 sites for O or N-glycosylation (6, 46). Human and bovine 
MUC15 are expressed in most tissues, but the functional role of MUC15 in 
normal physiology is not clear (45, 47), and there is no evidence that it is 
involved in lipid secretion.  
 
Xanthine oxidoreductase (XOR) is expressed in most cell types, but is 
expressed at very high levels in the lactating mammary gland (6). Many 
studies have focused on the functions and mechanisms of XOR regarding 
purine metabolism (48) and innate immunity (49), but the potential function of 





Fig. 1.4. Predicted topology of major proteins in MFGM. Integral proteins 
include MUC1, MUC15, CD36 and BTN. MUC1, MUC15 and BTN are type 1 
membrane proteins. BTN is a member of the immunoglobulin superfamily with 
two immunoglobulin-like domains (IgI, IgC1) and a single cytoplasmic tail. 
XOR and adipophilin (ADPH) are peripheral membrane proteins that do not 
have membrane anchors. These two proteins are probably associated with 
the cytoplasmic face of MFGM (6). ADPH, adipophilin; BTN, butyrophilin 1A1; 
CD36, cluster of differentiation 36; FABP, fatty acid binding protein; MUC1, 
mucin1; MUC15, mucin15; PAS 6/7, periodic acid Schiff glycoprotein 6/7; 
XDH/XO, xanthine oxidoreductase. (Mather, I. H., in press)  
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XOR in milk secretion is still unclear. XOR occurs as a homodimer of 300 kDa. 
Each subunit contains four redox centers; a molybdenum cofactor (Mo-Co), 
one FAD molecule, and two Fe2S2 clusters (48). XOR is recognized as the 
terminal enzyme of purine metabolism, catalyzing the hydroxylation of 
hypoxanthine to xanthine and of xanthine to urate (48). Additionally, XOR is a 
potential source of reactive oxygen species (ROS), which mediate not only 
ischemia-reperfusion injury but also function in innate immunity (49). XOR 
catalyzes the oxidation of xanthine and hypoxanthine to uric acid at the 
molybdopterin domain and oxidation of NADH at the FAD site (48). The 
reduction of NAD+ or molecular oxygen takes place at the FAD domain (48).  
 
In the bovine mammary gland, most XOR is in the cytoplasm, but a small 
fraction is membrane bound (50). Membrane-bound XOR is released by 
washing with salt or nonionic detergents indicating that it is loosely associated 
with the membrane (50). XOR may play a crucial role in milk fat globule 
secretion because the expression of XOR starts to increase in mid pregnancy, 
sharply increases at the onset of lactation, and decreases during involution 
(23). McManaman et. al. have suggested that XOR is a cytoplasmic protein 
during pregnancy and involution, which becomes concentrated in the apical 
plasma membrane during lactation in association with BTN (23). This 
XOR/BTN complex subsequently binds to ADPH on the lipid droplet surface, 
thus recruiting cytoplasmic lipid droplets to the apical plasma membrane (23). 
However, there is no evidence that ADPH interacts with either BTN or XOR, in 
 17   
vivo or in vitro. Interestingly, one strain of XOR-deficient mice (Xdh+/-) has a 
lactation phenotype, in that intracellular lipid accumulates, because lipid 
secretion is impeded (50).  
 
CD36 is an integral membrane protein with a molecular mass of 76 to 78 
kDa (6). CD36 is highly expressed in cells that store and secrete TAGs, such 
as differentiated adipocytes and mammary secretory epithelial cells (51). In 
the mammary gland, CD36 is concentrated in the apical plasma membrane, 
but is also expressed on basal/lateral surfaces of secretory epithelial cells and 
capillary endothelial cells (6, 51, 52). The cytoplasmic segment of CD36 
associates with FABP and as a complex may effect mammary gland 
differentiation (51). However, the possible involvement of CD36 in lipid 
secretion has not been studied. Phenotypic characterization of CD36-deficient 
mice has been reported in several tissues, but not in lactating mammary 
gland (53, 54).  
 
BTN is a type 1 integral membrane protein with a molecular mass of 
66,000. BTN is the most abundant protein in bovine MFGM that localizes only 
to the apical plasma membrane (34). Most members of the BTN gene family 
are type 1 integral membrane proteins (55) that may play multifunctional roles 
in diverse physiologies including lactation (56), selection and regulation of T-
cells in the immune system (57), and modulation of autoimmune disease (58, 
59). Human BTN genes consist of several subfamilies, which are BTN1A1, 
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BTN2A1 to 3, and BTN3A1 to 3 (60). BTN families 2 and 3 are expressed in a 
variety of tissues at low levels, but BTN1A1 is expressed at very high levels in 
the lactating mammary gland.  
 
The exoplasmic domain of BTN comprises two Ig folds, one of the 
intermediate type (IgI) closest to the N terminus, and a constant type (IgC1) 
close to the membrane anchor (55). Recent studies have shown that the IgI 
fold inhibites T-cell activation (59). Also, BTN in the diet may modulate the 
autoimmune disease, multiple sclerosis (MS), because of structural similarity 
between the IgI fold of BTN and the IgV fold of myelin oligodendrocyte 
glycoprotein (MOG), a brain-specific autoantigen (58).  
 
The cytoplasmic domain of BTN consists of a putative N-terminal coiled-
coil domain, a B30.2 domain, and cytoplasmic tail domain (55). This 
intracellular region is dominated by the B30.2 domain which comprises a 
distorted β-sheet sandwich core structure (61, 62), that is assumed to function 
as a protein binding module in many proteins (61, 62). According to amino 
acid sequence alignments, the secondary structures of the β-strands between 
BTN subfamily members are similar to each other, but the loop regions are 
very different suggesting that the loop regions may be involved in binding to 
individual partner proteins (61, 62).  
 
BTN may function in lipid droplet secretion, because ablation of BTN in 
 19   
mice causes a lactation phenotype. This phenotype is very similar to that of 
Xdh+/- mice, in which lipid droplets accumulate in the cytoplasm, and lipid 
secretion is impaired. Secreted lipid droplets are much bigger and very 
unstable compared with those of wild type mice (56, 63).  
 
ADPH is a member of the PAT family of proteins which binds to the outer 
surface of intracellular lipid droplets (6). ADPH was initially identified as 
adipose differentiation-related protein (ADRP), because it was thought to be 
only expressed in adipocytes (6, 64). However, further studies showed that 
ADPH is also found in many other cell types, in which synthesized lipid 
droplets accumulate (65). In the mammary gland, recent studies suggest that 
ADPH may play a role in lipid droplet secretion in association with XOR in 
mammary epithelial cells (23). Expression of ADPH correlates with increased 
formation of CLDs suggesting that there is a developmental relationship in 
secretory mammary epithelial cells between expression of ADPH and 
development of the secretory mechanism (66).  
 
PAS 6/7 is a bovine homolog of mouse milk fat globule-EGF factor 8 
protein (MFG-E8) with a molecular mass range of 43 to 58 kDa (6). MFG-E8 
is present in the apical plasma membrane during lactation and is upregulated 
during involution, at which point it binds to phosphatidylserine on the external 
surface of apoptotic cells (67, 68). In Mfge8 mutant mice, the mammary gland 
is inflamed and tissue remodeling is retarded during involution (67). However, 
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there is no known role for MFG-E8 in lipid droplet secretion. 
 
1.6. Three proposed models for molecular mechanism of lipid droplet 
secretion 
    There are three proposed models for molecular mechanism of lipid 
droplet secretion. In one model, Mather and Keenan have suggested that 
BTN localizes in the apical plasma membrane and interacts with XOR (6, 43, 
56). BTN and XOR are the most abundant MFGM proteins in many species, 
and the outer layer of the MFGM is directly derived from the apical plasma 
membrane (6). During secretion, BTN/XOR complexes are postulated to be 
required for formation of the outer envelope of the MFGM and expulsion of 
the lipid droplets into the lumen (6, 43, 56). Electron micrographs reveal that 
one face of isolated MFGM displays a membrane-like structure, but the other 
side of the membrane is coated with a thick layer of bound materials (37). 
This thick layer is composed of proteins, and appears as a fuzzy electron 
dense coat in isolated MFGM (39, 40). In addition, the lipid droplet remains a 
constant distance of 10-20 nm from the outer apical membrane bilayer in the 
process of lipid droplet secretion (4), thus suggesting that BTN as an integral 
membrane protein and XOR as a major cytosolic MFGM protein are recruited 
to form a layer of cytoplasmic protein, which is essential for lipid droplet 
secretion. However, this model did not specify where XOR is located, either 
on the lipid droplet surface, in the apical plasma membrane, or sandwiched 
between both places (Fig. 1.5 a).  





Fig. 1.5. Three proposed models for the molecular mechanism of milk-
lipid secretion. (a) BTN in the apical membrane interacts with XOR either in 
the apical membrane or on the surface of the lipid droplets, and the BTN/XOR 
complex is required for the formation of the outer envelope of the MFGM (6, 
43, 56). (b) XOR is sandwiched between BTN in the apical membrane and 
adipophilin (ADPH) on the surface of lipid droplet through disulfide bonds (23). 
(c) Milk-lipid secretion is regulated entirely by interactions between BTN 
molecules in both the apical membrane and the surface of lipid droplets (69). 
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In an alternative model, McManaman et. al. suggested that XOR is 
sandwiched between BTN in the apical plasma membrane and ADPH on the 
surface of the lipid droplet (23). The distribution of BTN, XOR, and ADPH 
overlap in immunofluorescence micrographs of lactating mammary tissue. 
However, the resolution was too low to establish their exact locations. 
Furthermore, they showed that disulfide bonds bridge XOR with BTN and 
ADPH in solubilized preparations of MFGM (Fig. 1.5 b).  
 
In a radically different model, Robenek et. al. proposed that BTN in the 
MFGM is concentrated in a network of ridges, which link BTN in the outer 
membrane layer to BTN on the droplet surface. This hypothesis was based 
on freeze-fracture Immunocytochemistry, which apparently showed that BTN 
was more abundant on intracellular droplets than the apical membrane and 
that BTN was distributed in a mirror image on the droplet surface and bilayer 
membrane (69). Thus, in this model, milk-lipid secretion is regulated entirely 
by interactions between BTN molecules localized in both the apical plasma 
membrane and the surface of intracellular lipid droplets (56) (Fig. 1.5 c). 
 
Even though the molecular mechanism for lipid droplet secretion has 
been controversial, there is convincing evidence through the use of gene-
targeting knock-down techniques that both BTN and XOR play pivotal roles in 
lipid droplet secretion (56, 63). Ablation of the BTN gene causes severe 
defects in the secretion of milk-lipid, the accumulation of lipid droplets in 
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mammary epithelial cells (Fig. 1.6), and a discontinuous and disrupted MFGM 
(56) (Fig. 1.7). Furthermore, one strain of XOR-deficient mice (Xdh+/-) has a 
similar lactation phenotype to that of Btn1a1-/- mice (Fig. 1.8) (63), which 
suggests that BTN may function in the lactating mammary gland by self-
association and/or by binding to XOR. 
 
To test the hypothesis that BTN specifically interacts with XOR and that 
the interaction has a crucial role in lipid droplet secretion and/or lipid 
metabolism in the mammary gland, I used biochemical and cellular 
approaches to identify the binding sites between two proteins. In addition, 
mutant mouse lines were used in attempts to identify the functional roles of 
BTN and XOR in lactating mammary gland. We tested the three models 
discussed above by:- 
(1) Developing in vivo (cell expression) and in vitro (GST pull-down) 
protein assays to identify the binding sites between BTN and XOR.  
(2) Localizing BTN and XOR in cultured cell lines, and in lactating 
mammary tissue from wild-type and BTN knock-out mice.  
(3) Expressing the interactive domain of BTN in vivo using adenoviral 
vectors to determine whether it acts as a dominant negative inhibitor of 
lipid secretion in transduced cells. 
(4) Attempting to ‘rescue’ the lactation phenotype of the BTN knockout 
mouse by reducing the amount milk fat and lipid droplet size by 
feeding conjugated linoleic acid (CLA) in the diet. 







Fig. 1.6. Light micrographs of lactating mammary tissue from Btn1a1+/+, 
Btn1a1+/-, and Btn1a1-/- mice. Differential interference contrast micrographs 
are shown. Lipid droplets in milk and tissue (ld) and adipocytes (adp) stain 
black with OsO4. (Bars: 50 µm in a–c; 10 µm in d–f) (56). 




Fig. 1.7. Electron micrographs of MFGM on lipid droplets in milk from 
Btn1a1+/+ and Btn1a1-/- mice. (a-c) MFGM on lipid droplets in milk. (a) 
micrograph of lipid droplet in wild type mice; (b, c) micrographs of lipid 
droplets in Btn1a1-/- mice. Bars, 1 µm (56).   





Fig. 1.8. Histological analysis of mammary glands of wild-type and Xdh+/- 
mice. (a-b) light micrographs. (a) wild-type mice, (b) Xdh+/- mice. (c-e) 
electron micrographs from Xdh+/- mice (63). 
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Chapter 2: Materials and Methods  
 
2.1. Materials 
Reduced glutathione, vitamins, amino acids, pepstatin A, leupeptin, Nα-p-
tosyl-L-lysine chloromethyl ketone, Nα-p-tosyl-L-phenylalanine chloromethyl 
ketone, aprotinin, digitonin, bovine serum albumin (BSA), dexamethasone, 
insulin from bovine pancreas, prolactin, epidermal growth factor (EGF), 3-
isobutyl-1-methyxanthine (IBMX), and adjuvants were obtained from Sigma 
(St. Louis, MO). The ESP® yeast protein expression and purification system 
was from Stratagene (La Jolla, CA). Glutathione-coated beads for the 
purification of glutathione S-transferase (GST) fusion proteins, thrombin, ECL 
Western blot detection reagents, supplies for surface plasmon resonance 
(SPR), cyanogen bromide-activated Sepharose 4B, and protein A-coated 
Sepharose beads were from Amersham Biosciences/GE Healthcare 
(Pittsburgh, PA). Rabbits were purchased from Covance (Princeton, NJ). 
Horseradish peroxidase-conjugated goat anti-rabbit secondary antibody 
(blotting grade), Triton X-100, SDS, acrylamide, IQTM SYBR® Green 
supermix, and bisacrylamide were from Bio-Rad (Hercules, CA). Protease 
inhibitor tablets were from Roche Applied Science. DNA polymerases, 
restriction enzymes, dNTPs, and trypsin were from Promega (Madison, WI), 
and phenylmethylsulfonyl fluoride and keyhole limpet hemocyanin were 
obtained from Calbiochem (Gibbstown, NJ). Lipofectamine 2000, rabbit anti-
green fluorescent protein (GFP) antibody, goat anti-(rabbit IgG)-FITC, goat 
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anti-(rabbit IgG)-Alexa568, Dulbecco’s modified Eagle’s medium (DMEM) and 
Roswell Park Memorial Institute (RPMI) Medium 1640, wheat germ agglutinin 
Alexa fluor® 633 conjugate, Nile Red and Dulbecco’s phosphate-buffered 
saline (PBS) were from Invitrogen (Carlsbad, CA). O.C.T compound was from 
Sakura Finetek U.S.A (Dublin, OH). In situ cell death detection kit, 
Fluorescein was from Roche (Florence, SC). All other chemicals were from 
Fisher. Four well LABTek chambers were from Nalge Nunc International 




2.2.1. Preparation of vectors encoding fluorescent fusion proteins of 
mBTN and mXOR 
Total RNA was purified from lactating mouse mammary gland using TRIzol 
reagent (Invitrogen) and XOR and BTN cDNAs prepared by reverse 
transcription PCR (RT-PCR) using the SuperScriptTM III One-Step RT-PCR kit 
from Invitrogen and specific primers complementary to the 5’ and 3’ mouse 
XOR and BTN open reading frames, respectively. The region of the cDNA 
encoding the processed form of mBTN with the N-terminal signal sequence 
removed was amplified with a second set of primers (Table 2.1), which 
introduced XhoI and XmaI restriction enzyme sites into the 5’ and 3’ ends, 
respectively, and the amplified product was cloned into the pECFP-C1 vector 
(Clontech Living Color vectors), which had been mutated so as to encode  
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Table 2.1. Primers used for PCR 
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monomerized ECFP (enhanced cyan fluorescent protein). The signal peptide 
of mBTN was then inserted 5’ of the ECFP gene using primers incorporating 
NheI and AgeI restriction enzyme sites at the 5’ and 3’ ends, respectively. 
The completed vector thus encoded the mBTN signal sequence, followed by 
the ECFP gene fused to the mature form of mBTN. Deletion constructs (Table 
2.2) were prepared by amplifying the appropriate regions of the open reading 
frame of BTN using the primers listed in Table 2.1. A vector encoding mXOR 
with monomerized EYFP (enhanced yellow fluorescent protein) at the C 
terminus was constructed using primers encoding NheI and XmaI restriction 
enzyme sites at the 5’ and 3’ ends, respectively (Table 2.1 and 2.2), and the 
amplified product cloned into the pEYFP-N1 vector (Clontech). Vectors 
encoding separate domains of mouse XOR (Fe2S2, FAD, Mo-Co, and 
Fe2S2/FAD) and ADPH with monomerized EYFP at the C terminus were 
constructed using primers encoding NheI and XmaI restriction enzyme sites 
at the 5’ and 3’ ends, respectively (Table 2.1 and 2.2), and the amplified 
product cloned into the pEYFP-N1 vector (Clontech). All PCR products were 
verified by sequencing.  
 
2.2.2. Cell culture  
HEK 293T cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
with glutamine, 10% FBS, 1 mM sodium pyruvate, and 1% antibiotics at 37 °C 
in a 5% CO2 incubator. HC 11 cells were maintained in 10% bovine calf serum 
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Table 2.2. Summary of recombinant vectors 
 

























GST fusion proteins with the 
following protein domain at 
the C terminus: 
 
the cyto domain of mouse BTN1A1 
the cyto domain of mouse BTN1A1 
with 






T269-G285; P480-P524 (mB30.2) 
 
the cyto domain of bovine BTN1A1 
the bovine BTN1A1 B30.2 domain 
the human BTN1A1 B30.2 domain 
the cyto domain of human BTN1A1 
the cyto domain of human BTN2A1 
the cyto domain of human BTN3A1 























Living Color Vectors ECFP or EYFP fusion proteins  
                                            
2 The numeric positions of amino acid residues are taken from the following sequences in the 
NCBI Database: mouse BTN1A1, NM 013483; mouse XOR, NM 011723; bovine BTN1A1, 
NM 174508; human BTN1A1, NP 001723; human BTN2A1, NM 007049; human BTN3A1, 
NM 007048; human RoRet, NM 006355; mouse ADPH, 11520.  




























mouse BTN1A1 whole protein with 
ECFP at the N- terminus, after the 
signal sequence 
mouse BTN1A1 whole protein with 
EYFP at the C- terminus 
mouse BTN1A1 with ECFP at the N-
terminus, after the signal sequence 






mouse XOR whole protein with 
EYFP at the C-terminus 
Fe2S2 centers of mouse XOR with 
EYFP at the C-terminus 
FAD of mouse XOR with EYFP 
at the C-terminus 
Mo-Co of mouse XOR with EYFP 
at the C-terminus 
Fe2S2/FAD of mouse XOR with 
EYFP at the C-terminus 
mouse ADPH whole protein with 
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(CS) in RPMI 1640 with 10 ng/ml insulin, 10 ng/ml epidermal growth factor 
and 2 mM L-glutamine. Cells were maintained at 37 °C in 95% air and 5% 
CO2, and the medium replaced once every 2 days. Cells were split 1:6 when 
at or near confluency. Cells were treated with 1 µM dexamethasone, 5 µg/ml 
insulin, and 5 µg/ml prolactin after 2 days of growth in EGF-containing 
medium (10 ng/ml) to induce the expression of XOR. 3T3-L1 cells were 
cultured in DMEM containing 10% CS in 5% CO2 at 37 °C. Two days after 
complete confluency (day 0), differentiation was induced by changing the 
medium to DMEM containing 10% CS plus 0.0115 g/ml 3-isobutyl-1-
methyxanthine (IBMX), 5 µg/ml insulin and 1 µM dexamethasone. After 48 h 
(day 2), the medium was replaced with DMEM containing 10% CS plus 5 
µg/ml insulin. On day 4, the medium was replaced with DMEM containing 
only 10% CS, and cells fed with 10% CS/DMEM every two days. Full 
differentiation was achieved by day 8.  
 
2.2.3. Cell Expression Assay for Protein Binding 
HEK 293T cells were grown to 80–90% confluency in 20 x 10 x 10 mm 
LABTek culture chambers and co-transfected, using Lipofectamine 2000 
(Invitrogen), with pmXOR-EYFP and a pECFP-mBTN vector (0.15 µg, each), 
encoding either full-length ECFP-mBTN or deletion constructs (Table 2.1). 
Cultures were incubated overnight, and the cells then washed three times 
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with KHM buffer (20 mM HEPES, pH 6.5, 110 mM potassium acetate, and 2 
mM MgCl2). Micrographs of selected cells were recorded using a Leica 
DMIRE2 fluorescence light microscope employing excitation wavelengths of 
456 nm for ECFP and 500 nm for EYFP and separately visualizing the 
fluorophores between 426 and 450 nm and 488 and 512 nm, respectively. 
KHM buffer containing 20 µM digitonin was then added to permeabilize the 
plasma membrane. Soluble fluorescent fusion protein was allowed to diffuse 
out of the cells, and a second set of micrographs was recorded after there 
was no further change in the fluorescence signal (3–5 min). Transfection 
efficiencies were in the 50–70% range for each experiment, and ~90% of the 
doubly transfected cells in any one microscope field displayed the 
fluorescence patterns described. 
 
2.2.4. Cell fractionation 
Cells were suspended in 3 mM imidazole buffer, pH 7.4, containing 250 
mM sucrose, 0.5mM EDTA, and proteinase inhibitors, and mechanically 
disrupted by passage through a 27-gauge needle (10 times). The post-
nuclear supernatants were fractionated into membrane and cytosol fractions 
by centrifugation at 100,000 gav for 1 h and analyzed by Western blotting. 
Fusion proteins on the blots were detected with cross-reactive antibody to 
GFP (Invitrogen) diluted 1 to 2,500 fold, followed with a 1 to 10,000 fold 
dilution of goat anti-(rabbit IgG) horseradish peroxidase conjugate. 
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2.2.5. Immunoprecipitation 
For immunoprecipitation from HEK 293T cells, cultures were grown in 10 
cm dishes and transfected with a total of 12 g of DNA using Lipofectamine 
2000. Control and transfected cells were harvested in Dulbecco’s PBS 
(Invitrogen) with proteinase inhibitors and mechanically disrupted by passage 
through a 27-gauge needle a total of 10 times. The nuclei were removed by 
centrifugation at 1,000 gav for 10 min at 4 °C, and the protein concentration of 
the postnuclear supernatants was adjusted to 2.4 mg/ml. RIPA buffer (2X) 
was then added so that the final concentrations of the constituents were 
protein 1.2 mg/ml, 50 mM Tris-HCl, pH 7.4, 40 mM NaCl, 1.0% (v/v) Nonidet 
P-40, 0.5% (w/v) sodium deoxycholate, and 0.1% (w/v) SDS. The mixtures 
were incubated at 4 °C with end-over-end stirring f or 10 min, the detergent-
soluble extracts were recovered by centrifugation at 16,000 x gav for 5 min 
and then precleared by incubation with protein A-coated beads at 4 °C for 1 h 
(20 µl of beads per 1.2 ml of RIPA buffer extract). To ensure optimal 
precipitation of potential XOR-BTN complexes, protein A-Sepharose beads 
(GE Healthcare) were titrated with rabbit polyclonal antibody to mXOR to 
determine the minimum amount of antibody required to precipitate all of the 
XOR from the RIPA buffer extracts. Immunoprecipitates were collected on the 
beads by incubating 20 µl of optimally coated XOR-antibody/protein A beads 
with 1.0 ml of each RIPA buffer extract, overnight, at 4 °C with gentle 
agitation. The beads were then washed three times with ice-cold PBS with 
proteinase inhibitors, and the bound protein was dissolved in SDS-PAGE 
 38   
buffer at 95 °C for 3 min and analyzed by SDS-PAGE and Western blotting. 
For immunoprecipitations from lactating mammary tissue, total membrane 
fractions were collected from the postnuclear supernatants of tissue 
homogenates. After washing once with TBS containing proteinase inhibitors, 
the microsomal membranes were extracted with RIPA buffer, and the 
immunoprecipitations were conducted on the clarified RIPA buffer extracts, 
essentially as described above for HEK 293T cells. The immunoprecipitations 
were repeated with total membrane fractions from three wild-type (Btn1a1+/+) 
and three Btn1a1-/- C57/Bl6 mice, all at day 10 of lactation. 
 
2.2.6. Expression and Purification of Recombinant Proteins 
Recombinant proteins were expressed in Schizosaccharomyces pombe, 
because the genome does not contain the XOR gene. Potential interactions 
between BTN and endogenous XOR were thus avoided. cDNAs were 
inserted 3’ to the GST gene in the pESP-1 vector supplied with the ESP-
Yeast Protein Expression and Purification System (Stratagene) (Table 2.2 for 
details, definitions, nomenclature, and abbreviations for the vectors used). 
Deletion constructs were prepared using PCR (Table 2.1 for primer pairs). 
SP-Q01 S. pombe cells were transformed with the completed vectors and 
grown in 1L cultures, as recommended by the manufacturer. In initial 
experiments, cells were resuspended in a mixture of 140 mM NaCl, 2.7 mM 
KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4 (PBS1) and lysed by vortexing 
with glass beads for 5–7 min in the presence of proteinase inhibitors [1 mM 
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phenylmethylsulfonyl fluoride, 1 µl/ml aprotinin (8.2 IU/ml), 1 µM pepstatin A, 
100 µM leupeptin)] and 0.5% (v/v) Triton X-100. In later experiments, 
improved yields of protein (6–10 mg of protein/l) were obtained by 
resuspending the cells in a modified lysis buffer (150mM NaCl, 0.5mM EDTA, 
50mM Tris-HCl, pH 7.4, Roche Applied Science protease inhibitors, 1mM 
phenylmethylsulfonyl fluoride, and 1 µl/ml aprotinin (8.2 IU/ml) and breaking 
the cells with a French press. Lysates were clarified by centrifugation at 
17,000 x gav for 30 min, followed by 100,000 x gav for 1 h in a Beckman model 
XL-90 ultracentrifuge. Recombinant proteins were purified by chromatography 
on glutathione resins following standard procedures. 
 
2.2.7. Preparation of Thrombin-cleaved Proteins 
GST was removed from the recombinant proteins by digestion with 
thrombin (GE Healthcare). Batches of purified fusion protein (approx. 5mg) 
were rebound to glutathione-Sepharose beads and incubated overnight with 
gentle agitation at 22 °C in 5.0 ml of 20 mM Tris-H Cl buffer, pH 8.4, 
containing 150 mM NaCl, 2.5 mM CaCl2, and thrombin (10 NIH enzyme 
units/mg of fusion protein). The recombinant protein was recovered from the 
supernatant, and the thrombin was removed by gel filtration on Superdex 200. 
 
2.2.8. In Vitro Glutathione Bead Binding Assay for Protein-Protein 
Interactions  
GST fusion proteins at final concentrations of 0.01 – 2 µM were bound to 
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0.2 ml (packed volume) of glutathione-coated beads in 0.5–1.0 ml of 50mM 
Tris-HCl buffer, pH 7.4, for 3 h at 4 °C, and the b eads were then washed 
three times with 1.0 ml aliquots of PBS. For the binding assays, the beads 
were divided into 20 µl portions and incubated overnight with XOR purified 
from bovine milk (bXO) (0.1–2 µM, monomeric Mr) in a total volume of 1.0 ml 
at 4 °C, with end-over-end stirring, in 1.5 ml Eppe ndorf tubes. The beads 
were then briefly washed three times with 1.0 ml aliquots of ice-cold PBS and 
heated to 95 °C in SDS-PAGE sample buffer. Aliquots  of the centrifuged 
supernatants were analyzed by SDS-PAGE, together with known amounts of 
fusion protein and bXOR as standards (0.5 – 8 µg). Gels were stained with 
Coomassie Blue and destained in 10% (v/v) acetic acid, and amounts of 
fusion protein and bXOR in the samples were determined using Quantity One 
1-D Analysis software (Bio-Rad). Binding was assayed either with constant 
amounts of fusion protein on the beads and increasing amounts of bXOR or 
with increasing amounts of fusion protein on the beads and saturating 
amounts of bXOR. Association and dissociation constants (KA and KD) were 
determined from the binding data by non-linear regression curve fit 
(hyperbola) using Prism version 5.0 software (Graphpad Software Inc.). 
 
2.2.9. FPLC Gel Filtration  
Proteins were separated by FPLC in a Superdex 200 HR prepacked 
column (1 X 30 cm) equilibrated with TBS, pH 7.4. For Mr estimations, the 
column was calibrated using the following protein standards; thyroglobulin 
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(669,000), ferritin (440,000), aldolase (158,000), bovine serum albumin 
(67,000 and dimer), ovalbumin (43,000), chymotrypsinogen A (25,000), and 
ribonuclease A (13,700). 
 
2.2.10. Surface Plasmon Resonance (SPR)  
The binding of bXOR to GST fusion proteins in real time was evaluated 
by SPR using a Biacore 3000 Biosensor (GE Healthcare, Biacore, Uppsala, 
Sweden). Carboxymethyldextran sensor chips (CM5) in flow cells 1 and 2 
were coated with 14000 –15000 resonance units (RU) of monoclonal anti-
GST antibody by standard amine coupling techniques according to the 
manufacturer’s instructions (Biacore). GST fusion proteins were captured on 
the chips at a level of 50 RU by injecting an aliquot of GST alone (0.5 µg/ml) 
into flow cell 1, and GST fusion proteins (1.0 µg/ml) into flow cell 2, 
respectively, in HBS-EP buffer (10mM HEPES, 150mM NaCl, 3mM EDTA, 
and 0.005% (v/v) surfactant p20, pH 7.4, filtered through a 0.2 µm filter and 
degassed before use). The kinetics of binding of bXOR to the immobilized 
GST fusion proteins were evaluated at a flow rate of 30 µl/min at 25 °C to 
minimize mass transport effects. bXOR at concentrations from 0 to 500 nM, in 
60 ul aliquots, was injected into flow cells 1 and 2, and the association and 
dissociation rates were recorded for up to 6 min. To assess the effect of pH 
on binding kinetics, bXOR was diluted in HBS-EP buffer adjusted to pH 6.0, 
6.5, 7.0, 7.4, or 8.0 with HCl or NaOH, and the association and dissociation 
analyses were performed as described above. The effect of salt on binding 
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was similarly determined by using HBS-EP buffer containing variable 
amounts of NaCl. Chip surfaces were regenerated by removing GST proteins 
with 50 µl injections of 10mM glycine-HCl buffer, pH 2.2. Sensorgrams were 
analyzed with BIAevaluation version 3.2 software (Biacore). Signals from the 
reference channel (GST) were subtracted from the channel containing GST 
fusion proteins to correct for refractive index changes, injection noise, and 
nonspecific binding to the reference surface. The signal obtained with a blank 
injection of HBS-EP buffer alone was then subtracted from the resulting data. 
Data were globally fitted to the Langmuir model for 1:1 binding and analyzed 
for significance by Student’s t test. 
 
2.2.11. Tissue extraction 
Mice were killed on day 10 of lactation by asphyxiation in CO2, and all of 
the mammary glands were excised and weighed. Three volumes of Tris-
buffered saline (TBS; 10 mM Tris-HCl, 140 mM NaCl, pH 7.2) containing 
proteinase inhibitors [0.1 mM phenylmethylsulfonyl fluoride, 0.1 mM Nα-p-
tosyl-L-lysine chloromethyl ketone, 0.1 mM Nα-p-tosyl-L-phenylalanine 
chloromethyl ketone, 1.0 ml/100 ml (8.2 IU/ml) aprotinin, and 1 mM ε-
aminocaproic acid] were added per g of tissue. The tissue was minced finely 
and homogenized on ice using a Polytron homogenizer by giving five pulses 
of 10 s each at a speed setting of six. Homogenates were centrifuged at 
1,000 x gav for 10 min at 4 °C to obtain sediments, operationa lly called the 
nuclear pellet. The postnuclear supernatants were further centrifuged at 
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100,000 x gav at 4 °C for 1 h, and the resulting po stmicrosomal supernatants 
and sediment membrane fractions were retained for analysis.  
 
2.2.12. XOR Assays 
XOR was assayed aerobically in 100 mM sodium phosphate buffer, pH 
7.2, containing 10% (v/v) dimethyl sulfoxide and 150 µM xanthine at 37 °C. 
The conversion of xanthine into uric acid was followed at 293 nm using a 
PerkinElmer Life Sciences Lambda 25 spectrophotometer. Enzyme activity 
(IU) was calculated using a molar extinction coefficient for uric acid under the 
assay conditions of 12.5 X 103 M-1 cm-1. Protein was assayed by the 
bicinchoninic acid (BCA) method, using bovine serum albumin as a standard. 
 
2.2.13. Immunofluorescence microscopy 
Lactating mice were killed by asphyxiation in CO2, and all of the 
mammary glands were excised. Mammary tissues were fixed in 4% 
paraformaldehyde, and embedded in OCT (Optimal Cutting Temperature) 
compound and frozen in isopentane surrounded with liquid nitrogen. The 
frozen tissue was sectioned into 16 µm sections. Thin sections of mammary 
tissue were permealized with 0.2 % Triton X-100 for 15 min. The permealized 
tissues were treated with blocking solution (2 % BSA in PBS/0.2% Triton X-
100) for 1 h, and then incubated with primary antibody diluted 1 to 100-fold in 
the blocking solution for 2 h. The sections were washed with PBS 5 times, 
and then incubated with secondary antibody diluted 1 to 500-fold in blocking 
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solution for 1 h. Sections were finally washed with PBS five times and 
examined using a Leica TCS SP5-X Laser scanning confocal microscope. 
Micrographs were recorded using excitation wavelengths of 488 nm and 
visualizing the fluorophores between 510-525 nm for EGFP. To separately 
visualize ECFP and EYFP, excitation wavelengths of 458 and 512 nm, were 
used, respectively, and the fluorophores were visualized at emission 
wavelengths between 470 and 480 nm, and 525 and 540 nm. 
 
2.2.14. Preparation of anti-peptide antibodies to mouse BTN and XOR  
Anti-peptide antibodies to mouse BTN and XOR were prepared as either 
described in Kreis et. al. with modification (70) or by a commercial company 
(Epitomics Burlingame, CA). The peptide sequences used were as follows:- 
the C-terminus of mouse BTN (SGD KDTLHSKLIPFSPSQAAP), a region of 
mouse BTN B30.2 domain (CRENVVKKGFDPMTPDNGF), and the C- 
terminus of mouse XOR (QFTTLCATGTPENCKSWSVRI).  
 
2.2.15. Fluorescence recovery after photobleaching (FRAP) and 
Fluorescence loss in photobleaching (FLIP) 
Milk-lipid droplets containing expressed mBTN-EGFP were placed on 
coverslips, and kept at 37°C. Imaging was performed  with a Leica TCS SP5-
X Laser scanning confocal microscopy by using the 488 nm line of an Argon 
laser. A small circular area (2 µm diameter) on the surface of the droplet was 
photobleached at 488nm using maximum laser power. Three prebleach 
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images at 1 sec intervals were acquired before photobleaching. Fluorescence 
recovery was monitored at low laser intensity for 160 sec. FRAP experiments 
were performed on at least 25 milk-lipid droplets from 3 mice, and data were 
averaged to generate a single FRAP curve. 
    For FLIP analysis, milk-lipid droplets containing expressed mXOR-
ECFP were placed on coverslips, and kept at 37°C. I maging was performed 
with a Leica TCS SP5-X Laser scanning confocal microscopy by using the 
458 nm line of an Argon laser excitation/emission with x 50 laser power. Milk-
lipid droplets containing cytoplasmic inclusions and mXOR-ECFP were 
selected for analysis, and repetitively photobleached in a small rectangular 
area (2 µm diameter) at maximum laser power. Three prebleach images were 
acquired before photobleaching. Photobleaching was continued for 50 – 100 
sec. FLIP experiments were performed on at least 6 milk-lipid droplets from 4 
mice. 
 
2.2.16. Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
cDNA was prepared to test selected genes: mouse XOR, slc5a8, 
Tnfrsf12a, Apaf1, FAS, MFG-E8, ADPH, ATP1B1, slc44a3, and SPG21. Each 
cDNA was synthesized using a SuperScriptTM III One-Step RT-PCR kit from 
Invitrogen. For qRT-PCR analysis, 4 µl of diluted cDNA were combined with 
15 µl of a mixture composed of 10 µl 1x SYBR Green master mix (IQTM 
SYBR® Green Supermix), 0.8 µl each of 10 µM forward and reverse primers, 
and 4.4 µl DNase/RNase free water in a 96 well iCycler iQ Real-time PCR 
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Detection system (Bio-Rad). Each sample was run in triplicate and a 4-point 
relative standard curve (4-fold dilution) plus the non-template control were 
used. The reactions were performed in the following conditions: 2 min at 
50 °C, 10 min at 95°C, 40 cycles of 15 sec at 95°C,  and 1 min at 60°C. The 
presence of a single PCR product was verified by the dissociation protocol 
using incremental temperatures to 95°C for 15 sec p lus 65°C for 15 sec. Data 
were analyzed with 7900 HT Sequence Detection Systems Software (version 
2.2.3, Applied Biosystems). 
 
2.2. 17. Transduction of mouse mammary glands in vivo  
Mice were anesthetized by the intraperitoneal injection of avertin at a 
dosage of 125 to 250 mg/kg body weight. Glands were washed with 70% 
ethanol and distilled water. Glass micropipettes for infusion were prepared by 
pulling the glass tip over a Bunsen flame into a fine tip of 60 to 75 µm and the 
ends fire-polished to remove sharp edges. A stock of adenoviral vector (1.0 x 
107pfu/ml) was made by diluting the original adenoviral vector stock with 
storage buffer (10 mM Tris-HCl, pH 7.5, 10 mM histidine, 75 mM NaCl, 1 mM 
MgCl2, 100 µM EDTA, 0.5% v/v EtOH, 50% v/v glycerol). Final doses (1.0 x 
107
 
pfu) for number 4 mammary glands, as described by Russell. et al, (71) 
were made by diluting the 1.0 x 107
 
pfu/µl stock with 90 µl of sterile filtered 
Ringer's solution (156 mM NaCl, 8.1 mM Na2HPO4, 1.2 mM K2HPO4, 2.7 mM 
KH2PO4, 0.9 mM CaCl2, 0.5 mM MgCl2). This dilution was made immediately 
before the infusion to ensure the stability of the vectors. The solution was 
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loaded into a 50 µl glass micropipette, the tip was gently inserted into the 
nipple canal, and the solution was slowly injected into the luminal tissue 
spaces. Micropipettes were washed three times each with Ringer’s solution, 
70% ethanol and filtered Ringer’s solution between each vector infusion. 
Each gland was infused two times with 50 µl aliquots of vector, for a total of 
100 µl per gland.  
 
2.2.18. Animal care 
C57BL and CD1® mice were maintained on Formulab Diet 5008 (PMI 
Nutrition International, Richmond, IN), and water was available ad libitum. 
The knock-out BTN strain was created as described by Ogg et. al. (56), and 
the Xdh-deficient strain was obtained from T. Finkel (NIH) (24). CD1® mice 
were purchased from Charles River Inc (Wilmington, MA). and were used for 
infusion of adenoviral vectors. The first full day after parturition was counted 
as day 1 of lactation, and litters were adjusted to six pups for each experiment.  
 
2.2.19. Conjugated linoleic acid (CLA) study 
Two groups of lactating mice (Btn1a1+/+ and Btn1a1-/-) were fed either a 
control diet containing oleic acid (20g/kg), or a CLA diet, in which 6.67 g/kg 
oleic acid was replaced with 6.67g/kg CLA from day 6 to day 10 of lactation. 
Litter size was adjusted to 6 pups for each mouse. Milk samples were 
collected on day 10 of lactation and milk lipid percentage (vol/vol) was 
estimated by crematocrit (72). 
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2.2.20. Apoptosis 
Tissue sections from Btn1a1+/+, Btn1a1-/-, mice at day 10 of lactation 
and Btn1a1+/+ mice at day 2 of involution were analyzed by the TUNEL assay 
to identify apoptotic cells. Tissue sections were fixed in 4% paraformaldehyde, 
and prepared as described in the manufacture’s manual (In situ Cell Death 
Detection Kit, Fluorescein; Roche). Mammary tissue at day 10 of lactation 
was fixed as described in Section 2.2.13 and cut into 10 µm frozen sections. 
Sections were incubated with specific antibody to mouse cleaved caspase-3, 
followed by goat anti-(rabbit IgG)-Alexa568 as secondary detecting agent. 
 
2.2.21. Purification of XOR 
XOR was purified from bovine milk by the method of Sullivan et al. (73), 
omitting Triton X-100 from the electrofocusing step. 
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Chapter 3: Determination of the physical interaction between 
BTN and XOR 
 
3.1. Rationale 
BTN and XOR are abundant proteins in the milk of most species (6, 21, 
23, 34). BTN is a major integral protein found in the MFGM, which localizes to 
the apical plasma membrane (34, 37, 55). XOR is expressed in most cell 
types and at very high levels in the secretory epithelial cells of the lactating 
mammary gland (6, 74, 75). Ablation of the BTN gene causes severe defects 
in the secretion of milk-lipid and lipid droplets accumulate in the cytoplasm, 
which suggests that BTN is essential for the regulated secretion or 
metabolism of lipid droplets during lactation (56). In addition, one strain of 
XOR-deficient mice (Xdh+/-) has a similar phenotype to Btn1a1-/- mice (63). 
Therefore, BTN may function in lipid droplet secretion and/or lipid metabolism 
in the mammary gland by specifically binding to XOR. To determine whether 
the two proteins interact, and if so, to identify the binding sites, we developed 
in vivo cell expression and in vitro GST pull-down protein binding assays.   
 
3.2. In vivo cell expression assay using HEK 293T cells 
In order to determine the domain in BTN which binds to XOR, an in vivo 
cell expression assay was devised, in which fluorescent fusion proteins of 
mouse BTN (mBTN) and mouse XOR (mXOR) were expressed in HEK 293T 
cells, and transfected cells were treated with digitonin (Fig. 3.1). Digitonin  






Fig. 3.1. Experimental scheme to analyze the localization of BTN and 
XOR. Cells were co-tansfected with a plasmid encoding ECFP-mBTN and 
mXOR-EYFP, and treated with digitonin to remove unbound cytoplasmic 
protein. Most of the cytoplasmic mXOR-EYFP was washed out of the cells 
after treatment with digitonin, but mXOR-EYFP bound to ECFP-mBTN 
remained in the plasma membrane. The distribution of expressed ECFP-
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generates pores in membranes by binding to cholesterol, which is a major 
sterol in the plasma membrane. Thus, after digitonin treatment, most soluble 
cytoplasmic proteins are washed out, but proteins trapped or bound to 
organelles remain in the cells (Fig. 3.1). 
Vectors were prepared encoding mBTN (mBTN signal sequence, 
followed by ECFP fused to the mature form of mBTN) (pECFP-mBTN), and 
mXOR fused at the C-terminus to EYFP (pmXOR-EYFP) (Fig. 3.2). In HEK 
293T cells transfected with pECFP-mBTN, ECFP-mBTN was expressed and 
localized to the plasma membrane as expected, but was also expressed in 
intracellular sites (Fig. 3.3 a-c). The intracellular site was close to or 
associated with the trans-Golgi network, because mBTN-EYFP co-localized 
with the Golgi apparatus marker, galactosyltransferase-ECFP (Fig 3.3 a-c). In 
contrast, mXOR-EYFP was expressed throughout the cytoplasm (Fig. 3.3 d). 
That both ECFP-mBTN and mXOR-EYFP were expressed as full-length 
proteins was confirmed by Western blot (Fig. 3.3 e). Furthermore, as 
expected, ECFP-mBTN was in the membrane fractions (Fig. 3.3 e, lane 2), 
and mXOR-EYFP was in the soluble cytoplasmic fractions (Fig. 3.3 e, lane 6). 
Both expressed proteins were of the expected size (95 kDa for ECFP-mBTN, 
and 175 kDa for mXOR-EYFP) with little evidence of degradation. That 
mXOR-EYFP was expressed in the cytoplasm was confirmed by treatment of 
the cells with digitonin to permeabilize the cells and wash out soluble, 
cytoplasmic proteins. As expected for a membrane protein, ECFP-mBTN 
remained in the plasma membrane and in intra-cellular organelles after  




Fig. 3.2. Constructs used for cell expression protein-binding assay. (a) A 
vector was prepared encoding fluorescent mBTN by ligating cDNAs in the 
following order; cDNA encoding mBTN signal sequence was ligated to the 5’ 
end of ECFP, and the 3’-end of ECFP was ligated to the mature form of 
mBTN (pECFP-mBTN). (b) A vector encoding fluorescent mXOR was 








Fig. 3.3. Expression of mBTN-EYFP and mXOR-EYFP in HEK 293T cells. 
(a-c) Localization of a fraction of mBTN-EYFP in the plasma membrane and 
intracellular membranes close to the Golgi apparatus, and (d) localization of 
mXOR-EYFP in the cytoplasm. Cells were co-transfected with (a) pmBTN-
EYFP and (b) p-galactosyl- transferase-ECFP. (c), merged image. Cells were 
transfected with (d) pmXOR-EYFP. (e) Cell fractions were analyzed by 
Western blot (50 µg protein/lane) using antibody to GFP. Lanes 1-3, 
membrane fractions; lanes 4-6, cytosol fractions. Lanes 1 and 4, 
untransfected control cells; Lanes 2 and 5, cells transfected with pECFP-
mBTN; lanes 3 and 6, cells transfected with pmXOR-EYFP. Bars, 10 µm. 
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treatment with digitonin (Fig. 3.4 a-b). However, all of the mXOR-EYFP in the 
cells was removed by digitonin treatment (Fig. 3.4 c-d). To identify potential 
interactions between the two proteins, HEK 293T cells were transfected with 
pECFP-mBTN and pmXOR-EYFP together, and the cells were treated with 
digitonin. Even after treatment with digitonin, some of the expressed mXOR-
EYFP co-localized with ECFP-mBTN at the plasma membrane and Golgi 
region (Fig. 3.5).  
 
3.3. Co-immunoprecipitation in HEK 293T cells 
To determine whether the two proteins are physically bound to each 
other in vivo, total detergent extracts of transfected HEK 293T cells were 
immunoprecipitated with antibody to mXOR. Expressed mXOR-EYFP was 
specifically precipitated with antibody to mXOR (Fig. 3.6, lane 2-4), and as a 
control, expressed GFP was not co-precipitated with expressed mXOR-EYFP 
(Fig. 3.6, lane 3, 5). Using a specific antibody to the C-terminus of mBTN (56), 
mBTN was detected on blots of immunoprecipitates from cells transfected 
with plasmids encoding both ECFP-mBTN and mXOR-EYFP (Fig. 3.6, lane 4), 
thus confirming that mBTN and mXOR interact in vivo. Untransfected cells 
served as a control (Fig. 3.6, lane 1). 
 
3.4. In vivo cell expression assay with mutated forms of mBTN 
To determine which region of the cytoplasmic domain of mBTN is required for 
the interaction with mXOR, plasmids encoding mutated forms of ECFP-mBTN 





Fig. 3.4. In vivo cell expression assay: expression of ECFP-mBTN and 
mXOR-EYFP in HEK 293T cells. (a-d) Cells were transfected with either 
pECFP-mBTN (a and b) or pmXOR-EYFP (c and d) before (-) (a and c), and 
after (+) (b and d), treatment with digitonin. Bar, 10 µm.  





Fig. 3.5. Co-localization of ECFP-mBTN and mXOR-EYFP in HEK 293T 
cells. (a-f) Cells were co-transfected with pECFP-mBTN and pmXOR-EYFP. 
(a, c, and e), before (-); (b, d, and f), after (+) treatment with digitonin. Shown 
is the fluorescence signal for ECFP-mBTN (a and b), mXOR-EYFP (c and d), 
and merged image (e and f). Bar, 10 µm 
 




Fig. 3.6. Immunoprecipitation of ECFP-mBTN and mXOR-EYFP 
complexes in HEK 293T cells. Cells were co-transfected with pECFP-mBTN 
and pmXOR-EYFP in HEK 293T cells. Proteins were immunoprecipitated 
(i.p.) from RIPA buffer extracts with antibody to mXOR, separated by SDS-
PAGE (6% polyacrylamide gel), and first blotted with antibody to mBTN 
(middle blot). The blot was then stripped and reprobed with antibody to 
mXOR (top blot). Aliquots of the same immunoprecipitates were also 
separated by SDS-PAGE on a 10% polyacrylamide gel to resolve GFP 
(bottom blot). Immunoprecipitates from non-transfected cells (lane 1), cells 
transfected with pmXOR-EYFP (lane 2), pmXOR-EYFP and a vector 
encoding GFP (lane 3), and pmXOR-EYFP and pECFP-mBTN (lane 4). The 
RIPA buffer extract used for the immunoprecipitation of mXOR-EYFP and 
GFP was separated in lane 5 to validate the antibody to GFP (GFP control). 
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were co-transfected and expressed with pmXOR-EYFP in HEK 293T cells. 
The cytoplasmic domain of BTN comprises three domains; a coiled coil 
domain (stem region), the B30.2 domain, and cytoplasmic tail domain (Fig. 
3.7). ECFP-fused cytoplasmic domain-less BTN (ECFP-mBTN 269-524) did not 
co-localize with mXOR-EYFP in the plasma membrane, and all expressed 
protein was washed out of the cell following digitonin treatment. (Fig. 3.8, 
panel 1). Serial deletion of the C-terminal region of ECFP-mBTNcyto showed 
that the entire tail domain (480-524) is unnecessary for binding to mXOR-
EYFP (Fig. 3.8, panel 2). However, removal of the first C-terminal ten amino 
acid residues (470-479) in the B30.2 domain resulted in abnormal localization 
of ECFP-mBTN in intracellular vesicles and abrogated binding to mXOR-
EYFP (Fig. 3.8, panel 3). These results indicate that the B30.2 domain of BTN 
is a potential binding domain with XOR.  
 
3.5. Glutathione/GST pull-down assays between the cytoplasmic domain 
of BTN and purified bovine XOR 
The interaction between the cytoplasmic domain of BTN and XOR was 
confirmed by glutathione-S-transferase (GST) pull down assays. The N-
terminal region of the cytoplasmic domain of BTN was conjugated to the C-
terminus of GST and the GST fusion proteins bound to glutathione/agarose 
beads. XOR purified from bovine milk (bXOR) was used as a potential binding 
partner. Binding of bXOR to the whole cytoplasmic domain of mouse BTN 
(GST-mBTNcyto) was saturable with apparent KDs in the 50 nM range (Fig.  









Fig. 3.7. Domain structure of the cytoplasmic domain of mouse BTN. 
The cytoplasmic domain of BTN comprises three domains; a coiled coil 
domain (stem region), the B30.2 domain, and cytoplasmic tail domain 





Fig. 3.8. In vivo cell expression assay with mutated forms of mBTN. (1-3) 
Co-expression of full-length mXOR and mutated forms of mBTN in HEK 293T 
cells. In each panel, (a-c) before digitonin, (d-f) after digitonin. (1) ECFP-
mBTN∆269-524 (a and d) and XOR-EYFP (b and e); (2) ECFP-BTN∆480-524 (a 
and d) and XOR-EYFP (b and e); (3) ECFP-mBTN∆470-524 (a and d) and XOR-
EYFP (b and e). In each panel, (c and f, merged images). Bars, 10 µm.  
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3.9). Consistent with results from the cell expression protein binding assay, 
deletion of the tail domain of mBTNcyto ( 480-524) had no effect on the 
binding of bXOR at saturating concentrations of bXOR (Fig. 3.10 a, lane 4; 
compare with controls in lanes 1, 2). In addition, the stem region (269-285) 
did not have a role in binding to bXOR (Fig. 3.10 a, lane 7). However, deletion 
of 10 amino acids ( 470-479) from the C-terminal region of the B30.2 domain 
and deletion of 25 amino acids (2 putative α-helix domains) ( 286-310) from 
the N-terminal region abrogated the interaction (Fig. 3.10 a, lanes 5, 6). Most 
significantly, the B30.2 domain alone was sufficient for binding to bXOR (Fig. 
3.10 a, lane 7). Bead binding and cell expression protein binding assays for 
interaction between mouse or bovine XOR and wild type or mutated forms of 
mBTNcyto are summarized in Fig. 3.11. 
 
3.6. SPR to determine the affinity and kinetics of binding between XOR 
and BTN 
The binding of bXOR to GST-fused BTN in real time was evaluated by SPR 
using a Biacore 3000 Biosensor. The binding constant (KD) was calculated by 
measuring the association and dissociation rates (KD = kd / ka). Ligand (GST-
fusion proteins) was immobilized on a glutathione-coated SPR chip in a 
microflow cell, and then saturating amounts of analyte (bXOR) was injected 
over the ligand layer. As the analyte bound ligand, an increase in SPR signal 
(expressed in response units, RU) was observed. After a desired association 
time (saturation), a solution without the analyte (the buffer only) was injected, 






Fig. 3.9. Glutathione/GST pull-down assays between the cytoplasmic 
domain of mBTN and purified bovine XOR. Glutathione/agarose beads 
were loaded with GST-BTN fusion proteins and saturated with bXOR. After 
washing with PBS, the beads were boiled in SDS-PAGE buffer and the eluted 
proteins separated by SDS-PAGE. (a) Binding between GST-mBTNcyto (0.1 
nmol) and increasing amounts of bXOR (0 –1.0 µM dimer), to determine the 
KD and stoichiometry at maximal binding. (b) Densitometric data derived from 










Fig. 3.10. Glutathione/GST pull-down assays between wild-type and 
mutant forms of GST-mBTNcyto, and purified bovine XOR. (a) Analysis of 
binding between saturating amounts of bXOR and mutant forms of GST-
mBTNcyto. Lane 1, GST; lane 2, no protein; lane 3, GST-mBTNcyto; lane 4, 
GST-mBTNcyto 480–524; lane 5, GST-mBTNcyto 470–524; lane 6, GST-
mBTNcyto 269–310;480–524; lane 7, GST-mBTNcyto 269–285;480–524 (mB30.2) (n=3). 
Densitometric analysis of the results from three experiments (mean ± S.D.) 
are shown in the right panel. Band densities are normalized (100%) to GST-
mBTNcyto (lane 3).  
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Fig. 3.11. Summary of bead binding and cell expression assays for 
interaction between mBTNcyto and XOR. Regions of mBTNcyto that bound 
to XOR are indicated by green lines, and regions that did not bind are shown 
by red lines. For the cell expression protein binding assay, the vectors used 
were pmXOR-EYFP in combination with pECFP-mBTN (1), pECFP-
mBTN 507–524 (2), pECFP-mBTN 493–524 (3), pECFP-mBTN 480–524 (4), and 
pECFP-mBTN 470–524 (5). For the in vitro bead binding assay, the vectors 
used were pGST-mBTNcyto (1), pGST-mBTNcyto 493–524 (3), pGST-
mBTNcyto 480–524 (4), pGST-mBTNcyto 470–524 (5), pGST-mBTNcyto 269–
310; 480–524 (6), and pGST-mBTNcyto 269–285; 480–524 (mB30.2) (7). 
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 and the protein complex dissociated. As the analyte dissociated from the 
ligand, a decrease in SPR signal (expressed in response units, RU) was 
observed. From these association (ka) and dissociation rates (kd), the 
equilibrium dissociation constant (binding constant, KD) was calculated (Fig. 
3.12 a). GST-fusion proteins encoding either full-length bovine or mouse 
BTNcyto domains (GST-bBTNcyto and GST-mBTNcyto) were used as 
ligands and bXOR as analyte. Dissociation constants (KD) for GST-BTNcyto 
from either species at 25 °C were not significantly  different; the average for 
cow and mouse was 112 and 113 nM, respectively (Fig. 3.12 b). Dissociation 
constants for bXOR and GST-bB30.2 were statistically similar (101 nM) to the 
KDs for GST-BTNcyto from either species (Fig. 3.12 b), thus confirming that 
the B30.2 domain is necessary and sufficient for maximal interaction between 
the two proteins. Either SPR or the bead binding assay showed that binding 
was pH-dependent, because no binding was detected below pH 6.0 (Fig. 3.13 
a), and binding affinities increased 5–7-fold when the NaCl concentration was 
lowered from 150 to 20 mM (Fig. 3.13 b) 
 
3.7. In vitro bead binding assay to determine the interaction between 
bXOR and BTNs from different species 
The amino acid sequence of B30.2 domain between BTN families is 
highly conserved particularly in the β-sheet regions, but the loop regions are 
relatively variable between families (Fig 3.14). To investigate binding 
specificity within and across species, the whole cytoplasmic domain of bovine 





Fig. 3.12. Determination of equilibrium and kinetic rate constants for 
interaction between BTN proteins and bXOR by SPR. (a) Representative 
example of the biosensor analysis of binding of bXOR to GST-bBTNcyto. (b) 
Summary of binding characteristics for interaction between BTN fusion 
proteins and bXOR. KD values within each assay are not significantly different 
(p > 0.05; MIXED procedure, version 9.1, SAS Institute (Cary, NC)). The 
number of determinations is shown in parentheses. (Dr. Yinghua Zhang in 
University of Maryland Medical School, Baltimore conducted the SPR 
spectroscopy on a fee-for-service basis). 





Fig. 3.13. Effect of pH and salt on binding of bXOR to GST-bB30.2. (a) 
Effect of pH on binding of bXOR to GST-bB30.2. Solid line, SPR analysis (KA 
µM-1). Dotted lines, bead binding assay, using the following buffers: KH2PO4-
KOH, pH 4.5–5.5 (red); MES, pH 5.5–7.0 (purple); HEPES, pH 7.0–8.0 
(green); and Tricine, pH 8.0 –9.0 (blue). (b) Effect of NaCl on the binding of 
bXOR to GST-bB30.2 (KA µM-1). The effect of salt on binding was similarly 
determined by using HBS-EP buffer (pH 7.4) containing variable amounts of 
NaCl. (Collaboration with Dr. Yinghua Zhang in University of Maryland 
Medical School, Baltimore on a see-for-service basis). 
 





Fig. 3.14. Amino acid alignment between human BTN1A1, BTN2A1, and 
BTN3A1. The amino acid sequence of the B30.2 domain between BTN 
families is highly conserved in the β-sheet strand regions (arrows), but loop 
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and human BTN1A1, the B30.2 domain of human BTN1A1, and the entire 
cytoplasmic domain of human BTN2A1 and BTN3A1 were prepared. 
Additionally, GST fused to the predicted B30.2 domain of human RoRet 
(TRIM 56) was prepared to test potential interaction with a B30.2 domain 
outside of the BTN protein family. bXOR bound to the whole cytoplasmic 
domain of bovine and human BTN1A1 (Fig. 3.15, lane 1, 2) and the B30.2 
domain of human BTN1A1 (Fig. 3.15, lane 3). However, there was no 
interaction with human BTN2A1, BTN3A1, and the B30.2 domain of human 
RoRet (Fig. 3.15, lane 4-6). An assay with no fusion protein served as a 
control (Fig. 3.15, lane 7). These data suggest that BTN1A1 specifically 
interacts with XOR, and since BTN1A1 is highly expressed during lactation, 
the interaction between BTN1A1 and XOR may be essential for milk secretion 
during lactation in the mammary gland. 
 
3.8. Gel filtration of protein complexes to determine the oligomeric state 
of BTN and the apparent Mr values of the purified proteins, separately, 
and together as BTN-XOR complexes 
The apparent Mr values of the purified GST-fusion proteins, thrombin-
cleaved purified proteins and BTNcyto-XOR complexes were determined by 
gel filtration on Superdex 200 (FPLC). GST-bBTNcyto was eluted with 
apparent Mr values of 190,000 and 215,000, respectively which indicated that 
these proteins form tetramers (Fig. 3.16 a, example for GST-bBTNcyto, 
dotted blue line, summarized in Table 3.1). Because GST itself forms a dimer,  




Fig. 3.15. In vitro bead binding assay to determine the interaction 
between bXOR and BTNs from different species. Specificity of binding 
between bXOR and different orthologs and paralogs of BTN. Lane 1, GST-
bBTNcyto; lane 2, GST-hBTN1A1cyto; lane 3, GST-hBTN1A1-B30.2; lane 4, 
GST-hBTN2A1cyto; lane 5, GST-hBTN3A1cyto; lane 6, GST-
hRoRet(TRIM56)-B30.2; lane 7, no protein. Densitometric analysis of the 
results from three experiments (mean ± S.D.) are shown in the bar graph. 
Band densities were normalized (100%) to GST-bBTNcyto (lane 1). 
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Fig. 3.16. Gel filtration of protein complexes. (a-c) Samples were 
separated by FPLC on a 1 x 30 cm column of Superdex 200 in TBS, pH 7.4, 
and protein was detected at A280 nm. (a) GST-bBTNcyto (10 nmol) (dotted 
blue line) and GST-bBTN-bXOR complex (10 nmol) (black line). The SDS-
PAGE gel shows analysis of peak fractions. (b) GST-bBTNcyto (8 nmol) 
(dotted blue line), bBTNcyto (8 nmol) (dotted red line), and bB30.2 (8 nmol) 
(solid red line). (c) GST-bB30.2-bXOR complex; SDS-PAGE gel shows 
analysis of peak fraction (lane 2) in comparison with protein standards (from 
top to bottom, 250, 150, 100, 75, 50, 37, 25, and 20 kDa; lane 1).




Table 3.1. Protein Mr values estimated by gel filtration on Superdex 200. 
 
Underlined values indicate the most abundant species. Values in parentheses 
indicate the number of determinations, and values in square brackets indicate 
the approximate molecular weight of proteins within a prominent shoulder 
associated with a major peak. ND, not done. 
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GST was removed from GST-bBTNcyto by digestion with thrombin to 
determine whether bBTNcyto intrinsically oligomerizes. The entire 
cytoplasmic domain of bBTNcyto was eluted with a molecular mass of 48,000, 
which is 80% of the mass expected for a dimer (61,020) (Fig. 3.16 b and 
Table 3.1). However, the purified bovine B30.2 domain (bB30.2) was eluted 
with a molecular mass of 19,500, close to that expected for a monomer 
(23,437) (Fig. 3.16 b and Table 3.1). These data indicate that the fusion 
proteins form tetramers through separate dimeric interactions between the 
GST domains and dimeric interactions between the cytoplasmic domains of 
BTN. Furthermore, interactions between BTN molecules appear to be due to 
interactions within either the stem or tail regions, since the B30.2 domain was 
eluted as a monomer. The complex between the B30.2 domain and XOR, 
eluted with an apparent Mr value of 344,000, which indicates that two 
monomers of B30.2 domain are bound to one dimer of XOR. This confirms 
that the B30.2 domian itself is sufficient to bind to XOR (Fig. 3.16 c and Table 
3.1). 
 
3. 9. Identification of the domains in XOR that bind to the B30.2 domain 
of BTN 
    XOR is a homodimer of 300kDa. Each subunit contains four redox 
centers; a molybdo-pterin cofactor (Mo-Co), one FAD molecule, and two 
Fe2S2 centers (FeS). In order to determine the domains of XOR that bind to 
BTN, an in vivo cell expression protein binding assay, similar to the one 
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discussed in section 3.1, was used. Fluorescent fusion proteins of mouse 
BTN (ECFP-mBTN) and the separate domains of mouse XOR (FeS-EYFP, 
FAD-EYFP, and Mo-Co-EYFP) were expressed in HEK 293T cells and the 
cells were treated with digitonin. ECFP-mBTN and FeS-EYFP co-localized in 
the plasma membrane and Golgi apparatus even after treatment with 
digitonin (Fig. 3.17 c, f, and i). In contrast, neither expressed FAD-EYFP nor 
Mo-Co-EYFP co-localized with ECFP-mBTN after treatment with digitonin 
(Fig. 3.18). However, expressed FAD-EYFP still remained in cell organelles 
even after treatment with digitonin suggesting that the fusion protein was mis-
folded and was non-specifically bound to membrane structures (Fig. 3.18 b, 
e). Therefore, as an additional test, a construct containing both FeS and FAD 
domains (pFeS/FAD-EYFP) was prepared.  
    Co-expression of ECFP-mBTN and FeS/FAD-EYFP showed that 
FeS/FAD-EYFP bound to ECFP-mBTN, before and after treatment with 
digitonin (Fig. 3.19). These data suggest that the domain of XOR which binds 
to the cytoplasmic domain of BTN is located within the Fe2S2 centers, and 
possibly the FAD domain, but not the molybdo-pterin domain.  
 
3. 10. Confirmation, by immunoprecipitation, that the FeS domain of 
XOR binds to BTN  
    To confirm that BTN physically interacts with the FeS domain of XOR, 
total detergent extracts of HEK 293T cells, transfected with ECFP-mBTN and 
EYFP fusion proteins of separate domains of XOR, were immunoprecipitated  




Fig. 3.17. Co-expression of ECFP-mBTN and FeS-EYFP in HEK 293T 
cells. (a, b, c) ECFP-mBTN, and (d, e, f) FeS-EYFP were co-expressed in 
HEK 293 cells, and the cells treated with digitonin. (a, d, g) before treatment 
with digitonin (-), and (b, e, h) after treatment with digitonin (+). Enlarged 
images (boxes) (c, f, i). Bars, 10 µm. 
 





Fig. 3.18. Co-expression of ECFP-mBTN and either FAD-EYFP or Mo-Co-
EYFP in HEK 293T cells. (a-i) ECFP-mBTN (a, b, and c) and FAD-EYFP (d, 
e, and f) were co-expressed in HEK 293T cells, and the cells were treated 
with digitonin. (a, d, and g) before treatment with digitonin, and (b, e, and h) 
after treatment with digitonin. Enlarged images (box) (c, f, and i). (j-r) ECFP-
mBTN (j, k, and l) and Mo-Co-EYFP (m, n, and o) were co-expressed in HEK 
293T cells, and the cells treated with digitonin. (j, m, and p) before treatment 
with digitonin, and (k, n, and q) after treatment with digitonin. Enlarged 
images (box) (l, o, and r). Bars, 10 µm.  
 
 




Fig. 3.19. Co-expression of ECFP-mBTN and FeS/FAD-EYFP in HEK 293 
cells. ECFP-mBTN (a, b) and FeS/FAD-EYFP (c, d) were co-expressed in 
HEK 293T cells, and the cells treated with digitonin. (a, c, and e) before 
treatment with digitonin, and (b, d, and f) after treatment with digitonin; 
merged images (e, f). Bar, 25 µm.  
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with antibody to mBTN. Co-expressed ECFP-mBTN and FeS-EYFP were 
immunoprecipitated together with antibody to mBTN, and detected by 
Western blot using an antibody to GFP (Fig. 3.20, lane 1). Interestingly, 
expressed FAD-EYFP (65 kDa) also immunoprecipitated with ECFP-mBTN, 
which suggests that the FAD domain in XOR might share BTN binding sites 
(Fig. 3.20 lane 2). In agreement with this, expressed FeS/FAD-EYFP (85 
kDa) was immunoprecipitated with ECFP-mBTN. (Fig. 3.20, lane 4). However, 
pull down of total detergent extract of HEK 293T cells, expressing ECFP-
mBTN and Mo-Co-EYFP, with antibody to mBTN did not lead to precipitation 
of expressed Mo-Co-EYFP (105 kDa), confirming that the molybdenum 
domain does not bind to BTN (Fig. 3.20, lane 3). Cell expression protein 
binding assays and immunoprecipitation assays for interaction between 
mBTN and the separate domains of XOR are summarized in Table. 3.2. 
In summary, these data indicate that the Fe2S2 domain binds to BTN, 










Fig. 3.20. Immunoprecipitation of ECFP-mBTN and EYFP fusion proteins 
of separate domains of XOR from HEK 293T cell extracts. Proteins were 
immunoprecipitated from RIPA buffer extracts with antibody to mBTN, 
separated by SDS-PAGE (8% polyacrylamide gel), and blotted with antibody 
to GFP. Immunoprecipitates from HEK 293T cells transfected with pECFP-
mBTN together with pFeS-EYFP (45 kDa) (lane 1), pFAD-EYFP (65 kDa) 
(lane 2), pMo-Co-EYFP (105 kDa) (lane 3), and pFeS/FAD-EYFP (85 kDa) 
(lane 4). Green arrow, Ig heavy chain; blue arrow, ECFP-mBTN; black arrow, 
expected size of each fluorescent fused domain of XOR. 
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Table 3.2. Summary of cell expression assays and immunoprecipitation 
for interaction between mBTN and separate domains of XOR. 
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Chapter 4: Localization of BTN and XOR in mammary 
epithelial cells  
 
4.1. Rationale 
The intracellular distribution of BTN and XOR in the lactating mammary 
gland (6, 23, 43, 56, 69), and how localization of the two proteins is related to 
milk-lipid secretion are controversial (6, 23, 43, 56, 69). As discussed in the 
introduction, there are three models for the molecular mechanism of milk-lipid 
secretion. In one model, Mather and Keenan suggested that BTN localizes in 
the plasma membrane, and interacts with XOR (6, 43, 56). These putative 
BTN and XOR complexes are postulated to bind to other molecules on the 
lipid droplet surface, thus, precipitating formation of the outer envelope of the 
MFGM and expulsion of the lipid droplets into the lumen (6, 43, 56). However, 
this model does not specify where XOR is located, either on the lipid droplet 
surface, the apical plasma membrane, or sandwiched between both places. 
In an alternative model, McManaman et. al. suggested that XOR is 
sandwiched between BTN in the apical plasma membrane and ADPH on the 
surface of the lipid droplets in a complex stabilized by disulfide bonds (23). In 
a radically different model, Robenek et. al. proposed that milk-lipid secretion 
is regulated entirely by interactions between BTN molecules localized in both 
the apical plasma membrane and the surface of intracellular lipid droplets (69). 
Therefore, to determine the location of BTN and XOR in mammary cells, we 
expressed fluorescent forms of mBTN and mXOR, as fusion proteins in 
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cultured cells, and in lactating mammary glands using recombinant adenoviral 
vectors and expression plasmids. In addition, sections of lactating mammary 
gland were examined by immunofluorescence microscopy using specific 
antibodies to determine the location of endogenous BTN and XOR in a wild-
type and knock-out mouse strains.   
 
4.2. Distribution of expressed BTN and XOR in cell lines containing lipid 
droplets 
To determine the location of exogenously expressed BTN and XOR in 
cells, four cell lines were used: HEK 293T cells, 3T3-L1 cells (a fibroblast-like 
cell line which can be converted into adipocytes), MAC-T cells (a transformed 
bovine mammary epithelial cell line), and HC 11 cells (a mouse mammary 
epithelial cell line). Although HEK 293T cells do not have an intrinsic ability to 
accumulate lipid, the addition of oleic acid to the medium induces the 
formation of some small lipid droplets. 3T3-L1, MAC-T, and HC 11 cells 
produce large numbers of lipid droplets under appropriate conditions. All four 
cell lines were used to test the predictions of either Mather and Keenan (6, 43, 
56) or Robenek et. al. (69), to see if either BTN or XOR bind to the surface of 
intracellular lipid droplets.  
HEK 293T cells were transiently transfected with pECFP-mBTN and a 
plasmid encoding ADPH fused at the C-terminus to EYFP (pmADPH-EYFP). 
As discussed in the introduction, ADPH is a member of the PAT family of 
proteins, which associate with the surface of lipid droplets in many cell types 
 83   
(76). Thus, as expected, mADPH-EYFP was localized to the lipid droplets and 
the cytoplasm in HEK 293T cells treated with 50 µg/ml oleic acid (Fig. 4.1 d). 
However, ECFP-mBTN localized to the plasma membrane, and was not 
detected on the surface of the lipid droplets, even after the cells were treated 
with digitonin to wash out all unbound cytosolic protein, including soluble 
mADPH-EYFP (Fig. 4.1 a, b, and c). In an alternative procedure, fluorescence 
loss In photobleaching (FLIP) analysis was used. A specific region of the 
cytoplasm was continuously bleached, until all of the fluorescent signal 
associated with unbound, mobile mADPH-EYFP had been lost (green 
rectangle in Fig. 4.2 d-g). After photobleaching, there was no overlap between 
the immobile mADPH-EYFP on the lipid droplet surfaces and ECFP-mBTN 
(Fig. 4.2). Therefore, BTN does not have an intrinsic ability to bind to neutral 
lipid droplets in HEK 293T cells.  
However, HEK 293T cells, a human embryonic kidney cell line, may not 
be the most appropriate model system, because the cells may lack essential 
BTN binding factors, specific to mammary cells or associated with 
endogenous lipid droplets. Therefore, these experiments were repeated with 
the lipogenic cell line, 3T3-L1, and mammary cells (MAC-T and HC 11). 
Similar results were obtained with 3T3-L1 cells transduced with a 
recombinant adenoviral vector encoding mouse BTN fused to EYFP (Adv-
mBTN-EYFP) (an adenoviral vector was used because 3T3-L1 cells are 
refractory to transduction of plasmid DNA) (77). Cells were transduced during 
conversion to adipocytes (69). Two days after transduction, the cells were  




Fig. 4.1. Detection of ECFP-mBTN and mADPH-EYFP in HEK 293T cells. 
(a-i) HEK 293T cells were co-transfected with (a, b, c) pECFP-mBTN and (d, 
e, f) pmADPH-EYFP using lipofectamine 2000. (a, d, g) Before (-), and (b, e, 
h) after (+) treatment with digitonin. Enlarged images of the boxed area (c, f, i). 
Bars, 10 µm.  
 





Fig. 4.2. Detection of ECFP-mBTN and mADPH-EYFP in HEK 293T cells 
by following fluorescent loss in photobleaching (FLIP) analysis. Cells 
were co-transfected with pECFP-mBTN (a, d) and pmADPH-EYFP (b, e); 
Merged images (c, f). (a, b, c) before photobleaching; (d, e, g) after 
photobleaching. Photobleached region is shown by green rectangle (d-f). Bar, 
10 µm.  
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stained with nile red and the location of mBTN-ECFP was determined by 
confocal microscopy. mBTN-EYFP localized to the plasma membrane, but 
not to cytoplasmic lipid droplets (Fig. 4.3 a-c).  
The MAC-T cell line produces a very small amount of BTN and XOR, in 
the presence of lactogenic hormones [intensity (arbitrary unit) of 7000/2000 
vs. 100/200 (BTN/XOR) for mouse mammary cells vs MAC-T cells using 
microarray analysis] (personal communication Dr. Kadegowda), and 
synthesizes lipid droplets after treatment with oleic and palmitic acid. To 
determine the location of expressed BTN in MAC-T cells, the cells were 
transiently co-transfected with pECFP-mBTN and pmADPH-EYFP, and 
treated with oleic acid to stimulate accumulation of lipid droplets. mADPH-
EYFP was specifically localized to lipid droplets (Fig. 4.3 e), and ECFP-mBTN 
localized to the plasma membrane (Fig. 4.3 d). ECFP-mBTN was not 
detected on the surface of intracellular lipid droplets (Fig. 4.3 f).  
Even though MAC-T is a bovine mammary epithelial cell line, the cells do not 
produce much BTN or XOR, even in the presence of lactogenic hormones. 
However, HC 11 cells, a mouse mammary epithelial cell line, endogenously 
produce XOR in the presence of dexamethasone (10-6 M) (73). Therefore, to 
determine whether the presence of endogenous XOR affects localization of 
BTN, HC 11 cells were transduced with Adv-mBTN-EGFP. The cells 
transduced with Adv-mBTN-EGFP showed that mBTN-EGFP localized to the 
plasma membrane (Fig. 4.4 a) and was not present on intracellular lipid 
droplets suggesting that the location of BTN is not affected by endogenous  





Fig. 4.3. Detection of BTN in 3T3-L1 and MAC-T cells. (a-c). 3T3-L1 cells 
were transduced with Adv-mBTN-EYFP during differentiation into adipocytes, 
and treated with nile red to stain the lipid droplets. (a) mBTN-EYFP, (b) Nile 
red, (c) merged image. (d-f) MAC-T cells were co-transfected with pECFP-
mBTN and pmADPH-EYFP using lipofectamine 2000 (Invitrogen). (d) ECFP-
mBTN, (e) mADPH-EYFP, (f) merged image. Bars, 10 µm.   
 





Fig. 4.4. Detection of BTN in HC 11 cells. HC 11 cells were treated with 
dexamethasone (10-6 M) to induce XOR expression. After induction, the cells 
were transduced with Adv-mBTN-EGFP, and treated with nile red to stain lipid 
droplets. (a) mBTN-EGFP, (b) nile red, (c) merged image. Blue; DAPI staining 
(nuclei). Bar, 10 µm. 
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XOR (Fig. 4.4). Thus, under the conditions tested, BTN did not associate with 
intracellular lipid droplets in either 3T3-L1, MAC-T, or HC 11 cells (Figs. 4.3, 
4.4). As discussed later, these results are in conflict with Robenek et. al (69). 
Mather and Keenan suggested that BTN interacts with XOR either at the 
cell surface or on the surface of intracellular lipid droplets (6, 43, 56). To test 
these possibilities, the location of XOR was examined by expressing mXOR-
ECFP in 3T3-L1 and MAC-T cells. 3T3-L1 cells were also used to test the 
potential interaction of XOR with intracellular lipid droplets. The cells were 
transduced with Adv-mXOR-ECFP during conversion to adipocytes. mXOR-
ECFP localized to the cytoplasm, but most of it was removed by treatment 
with digitonin, indicating that XOR does not bind tightly to intracellular lipid 
droplets (Fig. 4.5 a-f). In MAC-T cells, expressed mXOR-ECFP was mainly 
detected in the cytoplasm, and most of it was washed out of the cytoplasm 
after treatment with digitonin (Fig. 4.5 g, j). However, mADPH-EYFP was still 
bound to intracellular lipid droplets after treatment with digitonin (Fig. 4.5 h, k).  
In summary, the above results showed that BTN is located in the plasma 
membrane and XOR is expressed in the cytoplasm in cultured cells (HEK 
293T, 3T3-L1, MAC-T, and HC11). Neither protein appears to interact with 
lipid droplets. Thus, these data do not agree with the predictions of either 
Mather and Keenan (6, 43, 56), or Robenek et. al. (69). However, binding of 
XOR or BTN to lipid droplets may require mammary-specific factors, which 
are not expressed in established cell lines. Therefore, the distribution of BTN 
and XOR was determined in lactating mammary glands in vivo by two  




Fig. 4.5. Detection of XOR in 3T3-L1 and MAC-T cells. (a-f) 3T3-L1 cells 
were transduced with Adv-mXOR-ECFP during differentiation, and treated 
with nile red to stain the lipid droplets. (a, d) mXOR-ECF, (b, e) nile red, (c, f) 
merged images. (a-c) Before (-), and (d-f), after (+) treatment with digitonin. 
(g-l) MAC-T cells were co-transfected with pmXOR-ECFP and pmADPH-
EYFP using lipofectamine 2000 (Invitrogen) and treated with digitonin. (g, j) 
mXOR-ECFP, (h, k) mADPH-EYFP, (i, l) merged images. (g-i) Before (-), and 
(j-l) after (+) treatment with digitonin. Bar, 10 µm. 
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independent methods. 
 
4.3. Localization of BTN and XOR in lactating mouse mammary glands  
The mammary gland is a unique model system to study secretory 
mechanisms because it is a skin gland, which is accessible for manipulation 
by the infusion of agents such as expression vectors and antibodies via the 
streak canal of the nipple. To localize BTN in the lactating mammary gland, 
Adv-mBTN-EYFP was introduced at day 17 of pregnancy into the mammary 
glands of Btn1a1+/+ mice through the streak canal of the nipple and the 
tissues were collected on the 2nd day of lactation. mBTN-EYFP localized to 
the apical plasma membrane as well as secreted milk-lipid in the lumen (Fig. 
4.6 a, d). In contrast, expressed mXOR-CFP was detected in the cytoplasm 
(Fig. 4.6 e), and did not co-localize with intracellular lipid droplets. These 
results are in agreement with the above data from cultured cells in which BTN 
is targeted to membranes, and XOR is present in the cytoplasm.  
In order to determine the distributions of endogenous BTN and XOR, 
sections of lactating mammary tissue were stained with specific antibodies to 
either proteins and examined by confocal microscopy. BTN was specifically 
detected in the apical plasma membrane of Btn1a1+/+ mice, and, as expected, 
no signal was detected in tissue from Btn1a1-/- mice (Fig. 4.7 a, e). 
Furthermore, BTN was present in the secreted, but not in intracellular lipid 
droplets (Fig 4.7 a, d). Endogenous XOR was detected in the cytoplasm, but 
was enriched in the apical plasma membrane in Btn1a1+/+ mice (Fig. 4.8 a, e).  
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Fig. 4.6. Detection of recombinant mBTN-YFP and mXOR-CFP in 
lactating mouse mammary gland. The #4 mammary glands of day 17-
pregnant mice were transduced with either (a-d) Adv-mBTN-EYFP or (e-g) 
Adv-mXOR-ECFP, and transduced tissues were collected on day 2 of 
lactation. Tissue was fixed in 4% (w/v) paraformaldehyde, embedded in OCT 
(Optimal Cutting Temperature) compound, and frozen in isopentane 
surrounded by liquid nitrogen. The frozen tissue was sectioned (10 µm), and 
examined by confocal microscopy: (a-d) mBTN-EYFP, (a) mBTN-EYFP 
(white single arrowhead), green; (b) nile red, red; (c) merged image; (d) white 
double arrowhead, secreted milk-fat droplet. (e-g) mXOR-ECFP: (e) mXOR-
ECFP (white arrow), yellow; (f) nile red, red; and (g) merged image. AL, 
alveolar lumen. Bars, 10 µm.   
 





Fig. 4.7. Detection of endogenous BTN in Btn1a1+/+ and Btn1a1-/- mice in 
lactating mouse mammary gland. Mammary tissue at day 2 of lactation was 
fixed as described in the legend to Fig. 4.6 and cut into 16 µm frozen sections. 
(a-d) Btn1a1+/+, (e-h) Btn1a1-/- mice. Sections were incubated with specific 
antibody to mouse BTN (56), followed by goat anti-(rabbit IgG)-FITC as 
secondary detecting agent. (a, e) BTN, (b, f) nile red stain for lipid droplets, (c, 
g) WGA-Alexa 633 stain for apical plasma membrane, (d, h) merged image. 
AL, alveolar lumen; white arrows, apical plasma membrane; white 
arrowheads, secreted lipid droplets. Bars, 20 µm.  
 




Fig. 4.8. Detection of endogenous XOR in Btn1a1+/+ mice by 
immunofluorescence microscopy. Lactating mammary gland from 
Btn1a1+/+ mice was fixed in 4% paraformaldehyde, and prepared as decribed 
in the legend to Fig. 4.7. Sections were incubated with a specific antibody to 
mXOR (56), followed by goat anti-(rabbit IgG)-FITC as secondary detecting 
agent. (a) XOR, (b) WGA-Alexa 633 stain for apical plasma membrane, (c) 
nile red stain for lipid droplets, (d) merged image, and (e) enlarged image of 
the boxed area in (d). White arrowheads, apical plama membrane; AL, 
aveolar lumen. Bar, 20 µm. (n=3). 
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However, in Btn1a1-/- mice, XOR is present throughout the cytoplasm and is 
not enriched in the apical plasma membrane (Fig. 4.9 a, e), presumably 
because its binding partner, BTN, is absent in the knock-out strain. These 
data strongly suggest that BTN recruits XOR to the apical plasma membrane. 
To confirm these possibilities, tissue sections from Btn1a1+/+ and Btn1a1-
/- mice were treated with digitonin to wash out of all of the unbound cytosolic 
XOR, and the residual XOR was detected by confocal microscopy. XOR still 
co-localized with WGA 633 (wheat germ agglutinin Alexa-633), a marker for 
the apical plasma membrane, after treatment of Btn1a1+/+ tissue with digitonin 
(Fig 4.10 a). However, all of the XOR was washed out of the Btn1a1-/- tissue 
(Fig 4.10 d), confirming that XOR interacts with BTN in the apical plasma 
membrane, and that loss of BTN allows XOR to move freely in the cytoplasm. 
Furthermore, z-stack analysis showed that secreting lipid droplets from 
mammary epithelial cells are surrounded by XOR indicating that the 
BTN/XOR complex in the apical plasma membrane surrounds the milk-lipid 
droplet during secretion (Fig. 4.11). 
    To confirm that XOR associates with the outer bilayer of the MFGM, 
rather than the lipid droplet surface, milk-fat droplets containing mXOR-ECFP 
in cytoplasmic inclusions were analyzed by FLIP. Btn1a1+/+ and Btn1a1-/- 
mice were transduced with Adv-mXOR-ECFP and milk was collected on day 
2 of lactation. Milk-fat droplets containing cytoplasmic inclusions were 
selected for analysis. Repetitive bleaching of one portion of the cytoplasmic 
inclusion (rectangle in Fig. 4.12) results in removal of all of the signal 




Fig. 4.9. Detection of endogenous XOR in Btn1a1-/- mice by 
immunofluorescence microscopy. Lactating mammary gland from Btn1a1-/- 
mice was stained with antibody to XOR as described in the legend to Fig. 4.8. 
(a) XOR, (b) WGA-Alexa 633 stain for apical plasma membrane, (c) nile red 
stain for lipid droplets, (d) merged image, and (e) enlarged image of the 
boxed area in (d). White arrowhead, cytoplasm; AL, aveolar lumen. Bar, 20 
µm. (n=3). 
 




Fig. 4.10. Detection of endogenous XOR in Btn1a1+/+ and Btn1a1-/- mice 
by immunofluorescence microscopy after treatment of the sections with 
digitonin. Sections of lactating mammary gland from Btn1a1+/+ and Btn1a1-/- 
mice were treated with digitonin to wash out cytoplasmic unbound proteins 
and stained with antibody to XOR as described in the legend to Fig. 4.8. (a, d) 
XOR; (b, e) WGA-Alexa 633 stain for apical plasma membrane; (c, f) merged 
image. White arrowhead, apical plasma membrane; AL, aveolar lumen. Bars, 
10 µm. (n=3). 





Fig. 4.11. Localization of endogenous XOR by confocal microscopy (Z-
stack). Lactating mammary tissue from a Btn1a1+/+ mouse was stained with 
antibody to XOR as described in the legend to Fig. 4.8. and examined by 
confocal microscopy (z-stack analysis). (a, e, i), XOR; (b, f, j), WGA-Alexa 
633 stain for apical plasma membrane; (c, g, k), nile red stain for lipid droplets, 
(d, h, l), merged image. White arrows, secreting lipid droplets. Bar, 25 µm. 
(n=3) 





Fig. 4.12. Fluorescence loss in photobleaching (FLIP) analysis of the 
mobility of mXOR-ECFP in milk-lipid droplets from Btn1a1+/+ and Btn1a1-
/- mice. Day 17-pregnant mice were transduced with Adv-mXOR-ECFP, and 
milk-fat droplets were collected on day 2 of lactation. Milk-fat droplets 
containing cytoplasmic crescents and mXOR-ECFP were used for FLIP 
analysis. (a, c) before; (b, d) after bleaching (white rectangle, bleached 
regions). Lipid droplets from (a, b) Btn1a1+/+, and (c, d) Btn1a1-/- mice. Single 
white arrowhead, the outer MFGM bilayer; double white arrowhead, the lipid 
droplet surface. Representative of one droplet from six separate experiments. 
(4 mice) Bars, 5 µm.  
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associated with the mobile fraction of mXOR-ECFP. Interestingly, a fraction of 
the expressed mXOR-ECFP was still detected in the outer membrane of the 
MFGM after bleaching of Btn1a1+/+ droplets (Fig. 4.12 a, b), whereas all the 
signal was lost in the Btn1a1-/- droplets (Fig. 4.12 c, d). Furthermore, no 
fluorescent mXOR-ECFP was detected on the droplet surface after FLIP. This 
is consistent with the above data (Fig. 4.8 - 4.10) showing that XOR interacts 
with BTN in the apical plasma membrane, and is not present on the lipid 
droplet surface.  
To confirm co-localization of BTN and XOR in the apical plasma 
membrane, both Adv-mBTN-EYFP and Adv-mXOR-ECFP were introduced at 
day 17 of pregnancy into the mammary glands of Btn1a1+/+ mice through the 
streak canal of the nipple. The expression of mBTN-EYFP and mXOR-ECFP 
was examined at day 2 of lactation. Expressed mBTN-EYFP localized in the 
apical plasma membrane (Fig. 4.13 a), and mXOR-ECFP was expressed in 
the cytoplasm (Fig. 4.13 b). However, expressed mXOR-ECFP was enriched 
in the apical plasma membrane compared to the cytoplasm, and co-localized 
with mBTN-EYFP (Fig. 4.13 b, d).  
 
4.4. Immunoprecipitation of BTN and XOR from extracts of lactating 
mammary gland 
All the above the data describe the distribution of BTN and XOR in vitro 
and in vivo, but they do not establish whether the two proteins are bound 
together in cells. To establish in vivo interaction between the two proteins,  





Fig. 4.13. Co-localization of expressed mBTN-YFP and mXOR-CFP in 
lactating mammary gland. (a-e) Lactating mammary gland was co-
transduced with adenoviral vectors, Adv-mBTN-YFP and Adv-mXOR-ECFP, 
and the expressed proteins localized in the tissue by confocal microscopy. (a) 
BTN-EYFP (green); (b) XOR-ECFP (red); (c) DAPI stain for nuclei and, WGA-
Alexa 355 stain for the apical plasma membrane; (d) merged image; (e) 
enlarged image of the boxed area in (d). White arrows, apical plasma 
membrane. Bar, 10 µm.  
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detergent extracts of membrane fractions, prepared from the lactating 
mammary tissue of both Btn1a1+/+ and Btn1a1-/- mice, were 
immunoprecipitated with antibody against mXOR. A band of protein that 
reacted with antibody to BTN was detected in the immunoprecipitates from 
wild-type mice (Fig. 4.14, lane 1), whereas there was no reaction with 
immunoprecipitates from Btn1a1-/- mice (Fig. 4.14, lane 2). About 37.5 ± 6.2% 
of BTN (mean and S.D. of three determinations) was bound to XOR, as 
determined by densitometric analysis of the detergent extracts before and 
after incubation with the antibody-coated protein A beads (Fig. 4.14, lanes 3 
and 5). Interestingly, XOR was also recovered in the immunoprecipitates from 
knock-out mice, indicating that XOR binds to membranes in the absence of 
BTN.  
 
4.5. Mobility characteristics of BTN in secreted lipid droplets determined 
by Fluorescence Recovery After Photobleaching (FRAP) analysis 
To measure the mobility of proteins in the bilayer of the MFGM, milk-fat 
droplets containing expressed mBTN-EGFP were used for FRAP analysis. 
Brief bleaching of one portion on the surface of the MFGM by laser light 
results in removal of most of the signal, and allows measurement of the 
mobility of unbleached molecules as they diffuse into the bleached area (Fig. 
4.15 a). The distribution of mBTN-EGFP on secreted milk-fat droplets was 
heterogeneous: in some droplets, mBTN-EGFP was “continuous” and evenly 
surrounded the entire surface (Fig. 4.15 b), and in others, mBTN-EGFP was  




Fig. 4.14. Immunoprecipitation of BTN-XOR complexes from the 
lactating mammary gland. Proteins were immunoprecipitated from RIPA 
buffer extracts with antibody to mXOR, separated by SDS-PAGE (6% gel), 
and first blotted with antibody to mBTN (bottom blot). The blot was then 
stripped and reprobed with antibody to mXOR (top blot). Shown are 
immunoprecipitates from a wild-type mouse (lane 1) and a  Btn1a1-/- mouse 
(lane 2). The corresponding RIPA buffer extracts, before and after incubation 
with the antibody-coated protein A beads, are shown for the wild-type mouse 
in lanes 3 and 5 and for the Btn1a1-/- mouse in lanes 4 and 6, respectively. 
(n=3) 
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Fig. 4.15. Fluorescence recovery after photobleaching (FRAP) analysis 
of the mobility of mBTN-EGFP in milk-lipid droplets from Btn1a1+/+ mice 
and the plasma membrane of HC 11 cells. Day 17-pregnant mice were 
transduced with Adv-mBTN-EGFP, and milk-fat droplets were collected on 
day 2 of lactation. Milk-fat droplets containing mBTN-EGFP were used for 
FRAP analysis. (a) Experimental scheme for FRAP analysis. Brief bleaching 
of one portion of the surface of the MFGM results in removal of most of the 
fluorescent signal, and allows measurement of the mobility of unbleached 
molecules, as they diffuse into the bleached region. (b-g) FRAP analysis from 
milk fat droplets containing mBTN-EGFP. (b-d) “continuous” and (e-g) 
“condensed” areas. (b, e), pre-bleach; (c, f), post-bleach; (d, g) recovery. Bars, 
5 µm. (h, i) The summary of the analysis of recovery rates after 
photobleaching from (h) “continuous” milk-fat droplets (n=25) (3 mice), and (i) 
HC 11 cells (n=11). Bars, 5 µm. (Collaboration with Dr. Brian Daniels, NIH) 
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in “condensed” areas and concentrated in limited regions (Fig. 4.15 e). In 
“continuous” areas, mBTN-EGFP was freely mobile in the bilayer with 
diffusion coefficients of 0.01 µm2/s and recovery rates of 100% (Fig. 4.15 b-d, 
h and Table 5.1), and was more mobile than that in the plasma membrane of 
HC 11 cells (Fig. 4.15 i and Table 5.1). However, mBTN-EGFP was less 
mobile in “condensed” areas (Fig. e-g and Table 5.1), which suggests that 
there are structural changes to the MFGM after secretion as suggested from 
the electron micrographs of Wooding et. al. (78). Thus, BTN is freely mobile in 
the bilayer membrane of MFGM in some areas (“continuous”) of secreted lipid 
droplets but less mobile in “condensed” regions. 




Table 4.1. Measurement of mobility of mBTN-EGFP in milk-fat droplets 
and HC 11 cells. 
 
Sample Recovery (R, %) Diffusion coefficient (µm2/s) 
Milk fat droplets 
 “continuous” (n=33) 
 “condensed” (n=12) 
 
HC 11 cells (n=11) 
 
101 +/- 4a 
19 +/- 7b 
 
108 +/- 7a 
 
0.012 +/- 0.002c 
0.005 +/- 0.002d 
 
0.006 +/- 0.002d 
 
Data in columns with different superscript letters are significantly different 
(P<0.05). a and b P<0.001; c and d P<0.05. 
 
In collaboration with Dr. Brian Daniels, NICHD, NIH. 
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Chapter 5: Functional significance of BTN/XOR interactions in 
the lactating mammary gland 
  
5.1. Rationale 
As discussed in Chapter 3 and 4, we characterized the physical 
interaction between BTN and XOR (79), and showed that they interact in the 
apical plasma membrane. However, these data do not establish any 
functional roles for BTN/XOR complexes in the lactating mammary gland. 
Therefore, to address the function of BTN and XOR in lactation, we 
determined whether expression of XOR correlated with the amount of BTN in 
cultured cells, or in Btn1a1+/+, Btn1a1+/-, and Btn1a1-/- mice, and attempted to 
block binding of endogenous XOR to BTN in vivo, to see if milk-lipid secretion 
was inhibited.  
 
5.2. Co-relationship between BTN and XOR in HC 11 cells 
To determine potential relationships between the expression of BTN and 
XOR, HC 11 cells were transduced with Adv-mBTN-EGFP, and the total 
amount and distribution of endogenous XOR determined in cell fractions. As 
discussed above, HC 11 cells endogenously express XOR after treatment 
with dexamethasone (73). Surprisingly, the total level of XOR was decreased 
by up to 50% in cells transduced with Adv-mBTN-EGFP, compared with cells 
transduced with Adv-EGFP, or non-transduced controls (Fig. 5.1 a, b). As 
expected, expression of BTN leads to a redistribution of XOR from the  





Fig. 5.1. Expression of BTN decreases the total amount of endogenous 
XOR in HC 11 cells and promotes binding of XOR to cellular membranes. 
HC 11 cells, grown in the presence of 10-6 M dexamethasone, were 
transduced with a vector encoding BTN-GFP (Adv-mBTN-GFP) (test), or GFP 
(Adv-GFP) (transduced control).  Untransduced cells served as a second 
control. (a) Total extracts, cytoplasmic and membrane fractions from HC 11 
cells were analyzed for XOR by Western blot. (b-d) Bar graph showing 
densitometric analysis of the blots shown above. Densities were normalized 
(100%) from untransduced cells. (b) total extracts, (c) cytoplasmic fractions, 
and (d) membrane fractions (n=5).  
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cytoplasm to membranes; cytoplasmic XOR was decreased by 50%, whereas 
membrane-bound XOR increased 2.5 fold compared with non-transduced 
cells. (Fig. 5.1 c, d). These data suggest that BTN regulates the amount of 
XOR in cells and influences its intracellular location.  
To confirm that over-expressed mBTN-EGFP binds to endogenous XOR 
in the plasma membrane and intracellular organelles, the distribution of the 
two proteins was determined in transduced HC 11 cells. mBTN-EGFP was 
specifically detected in the plasma membrane or intracellular organelles, and, 
as predicted, XOR relocated to mBTN-EGFP-containing intra-cellular 
organelles and the plasma membrane compared with non-transduced 
controls (Fig 5.2 a-d).  
To confirm the data, HC 11 cells over-expressing mBTN-ECFP were 
treated with digitonin to remove any soluble unbound XOR, stained with 
specific antibody to mXOR, and examined by confocal microscopy. Very little 
XOR was detected in the non-transduced cells (Fig. 5.2 e), but endogenous 
XOR was still bound to mBTN-ECFP in the plasma membrane and intra-
cellular organelles even after treatment with digitonin (Fig 5.2 f-h). Collectively, 
these  data  ind icate  that  BTN both  b inds  to  XOR in  ce l lu la r  
membranes and regulates the total amount of XOR in cells, at either the post-
transcriptional, or post-translational level. 
 
5.3. Intracellular XOR mRNA and protein accumulate in Btn1a1-/- mice 
To examine the relationship between BTN and XOR in lactating  




Fig. 5.2. Expression of BTN recruits cytoplasmic XOR to the plasma 
membrane and intra-cellular organelles in HC 11 cells. XOR was localized 
by immunofluorescence microscopy in either, (a) untransduced control cells 
or (b-d) cells transduced with Adv-mBTN-ECFP. (e-h) either untransduced 
control cells or those transduced with Adv-mBTN-ECFP, were treated with 
digitonin. (b, f) mBTN-ECFP, (c, g) XOR, and (d, h), merged images. White 
arrows, plasma membrane. Bars, 10 µm.  
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mammary tissue, the total amount of XOR in extracts from wild-type and 
mutant mouse lines was estimated by either Western blot or enzyme assay. 
The amount of XOR protein in Btn1a1-/- mice was 3 fold higher than in 
Btn1a1+/+ mice, and 2 fold higher than in Btn1a1+/- mice using Western blot to 
analyze for XOR (Fig. 5.3 a). Analysis of XOR activity in six genotypes 
(Btn1a1+/+, Btn1a1+/-, Btn1a1-/-, Xdh+/-, Btn1a1+/-/Xdh+/-, and Btn1a1-/-/Xdh+/-) 
showed that there is an inverse linear relationship between the amount of 
BTN and XOR in cells (Fig. 5.3 b). Thus, activity of XOR in the total extracts 
and the cytoplasmic fractions is increased by 3 fold and 6 fold respectively, in 
Btn1a1+/- and Btn1a1-/- mice, and is expressed at predictable levels in 
heterozygous animals (Fig. 5.3 c, d). Interestingly, enzyme activity increased 
by 2 and 2.5 fold respectively, in microsomal fractions from Btn1a1+/- and 
Btn1a1-/- mice, presumably because accumulated XOR passively absorbed to 
the membrane fraction (Fig. 5.3 e).  
The level of total XOR protein correlated with the amount of XOR mRNA. 
The amount of mRNA increased by 1.5 fold and 2 fold in Btn1a1-/- mice, 
compared with Btn1a1+/+ mice, as estimated by microarray and qRT-PCR, 
respectively, suggesting that BTN negatively regulates the amount of XOR in 
cells (mRNA and protein) as well as serving as a membrane anchor that binds 
directly to XOR (Fig. 5.4). 
 
5.4. Over-expression of the B30.2 domain acts as a dominant negative 
inhibitor in transduced mammary cells in vivo. 





Fig. 5.3. Amount of intracellular XOR mRNA and protein are inversely 
correlated with the expression of BTN. (a) Total extracts, cytoplasmic, and 
membrane fractions of tissue samples from Btn1a1+/+, Btn1a1+/-, and Btn1a1-/- 
mice were analyzed for XOR protein by Western blot. (b) Diagram showing 
the amount of XOR is inversely proportional to the amount of BTN. X-axis, 
measured XOR activity; Y-axis, predicted XOR activity. (c-e) Analysis of XOR 
activity in mammary extract from six different genotypes; (c) total tissue 
extracts, (d) cytoplasmic fractions, and (e) membrane fractions. (n=3) 
 





Fig. 5.4. The amount of XOR mRNA correlated with the level of total XOR 
protein.  Determination of XOR mRNA levels. microarray analysis (left) and 
qRT-PCR (right) (n=5). 
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To examine the functional relationship between BTN and XOR in lactating 
mammary epithelial cells, we over-expressed the B30.2 domain of BTN as a 
soluble protein to see if it would prevent binding of XOR to endogenous 
membrane-bound BTN, thus acting as a dominant negative inhibitor (Fig 5.5 
a). To test this, we designed a recombinant adenoviral vector separately 
encoding GFP and the soluble mB30.2 domain (Adv-mB30.2+EGFP), and 
infused it into mammary glands on day 18 of pregnancy (Fig 5.5 b). 
Adenoviral vectors separately encoding GFP and mB30.2 10 domain (Adv-
mB30.2 10+EGFP), and EGFP (Adv-EGFP) were used as controls (Fig 5.5 b). 
If soluble B30.2 inhibits binding of XOR to BTN, then lipid secretion should be 
inhibited and large lipid droplets should accumulate in the cytoplasm, as in 
Btn1a1-/- mice. As predicted, mammary epithelial cells over-expressing the 
cytosolic B30.2 domain (marked with GFP as reporter) accumulated large 
lipid droplets, which is similar to the phenotype of Btn1a1-/- mice (Fig. 5.6 e-g). 
However, lipid droplets in cells, expressing either mB30.2 10 or GFP were no 
larger than droplets in untransduced cells (Fig. 5.6 h-m). The size of 
intracellular lipid droplets (diameter and volume) was measured and 
compared with those in Btn1a1+/+ and Btn1a1-/- mice. The size of intra-cellular 
lipid droplets in the cells expressing the B30.2 domain approached those in 
Btn1a1-/- mice (Fig. 5.6 n). Whereas, lipid droplets in cells expressing 
mB30.2 10 and EGFP alone were the same size as those in Btn1a1
+/+ mice 
(Fig. 5.6 n). These data strongly suggest that the B30.2 domain, when over-
expressed as a soluble protein, inhibits the interaction between XOR and  





Fig. 5.5. Experimental scheme to test whether over-expression of the 
mB30.2 domain acts as a dominant negative inhibitor in vivo. (a) 
Schematic diagram showing how over-expression of cytosolic mB30.2 
domain could inhibit the binding of XOR to endogenous BTN in the apical 
plasma membrane. (b) Diagram showing the structure of the mB30.2 10 and 
B30.2 domain. Mammary glands were transduced on the 18th day of 
pregnancy with adenoviral vectors separately encoding GFP and either the 
soluble mB30.2 or mB30.2 10 domain, and transduced tissues examined on 
day 2 of lactation.  




Fig. 5.6. The mB30.2 domain acts as a dominant negative inhibitor when 
over-expressed in lactating mammary cells in vivo. (a-d) Morphology of 
day 2-lactating mammary glands from Btn1a1+/+ and Btn1a1-/- mice. (a, c) nile 
red stain for lipid droplets, (b, d) merged images; DAPI, blue (nuclei); WGA-
Alexa 633, blue-green; white arrowhead, intracellular lipid droplets. (e-m) The 
mammary glands of day 17-pregnant mice were transduced with adenoviral 
vectors separately encoding (e-g) mB30.2+EGFP, (h-j) mB30.2 10+EGFP, 
and (k-m) EGFP. Tissue sections were fixed in 4% paraformaldehyde, and 
prepared as described in the legend to Fig. 4.6. (e) mB30.2 and EGFP, 
green; (h) mB30.2 10 and EGFP, green (k) EGFP, green; (f, i, l) nile red; (g, j, 
m) merged images; DAPI, blue. White arrowheads, intracellular lipid droplets; 
AL, alveolar lumen. (n) Measurement of intracellular lipid droplets. The cells 
marked with GFP were selected and the diameter of thirty-five intracellular 
lipid droplets per mouse was measured by Image-Pro plus (Version 6.2). 
(n=3), Bars, 10 µm.  
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BTN in the apical plasma membrane, and thus acts in a dominant negative 
manner. 
 
5.5. Reducing fat content and lipid droplet size does not rescue the 
phenotype of Btn1a1-/- mice 
    Ablation of the BTN leads to accumulation of lipid droplets in the 
cytoplasm and inhibition of milk-lipid secretion from mammary epithelial cells 
(56). We postulated that this is because BTN is required for the envelopment 
of lipid droplets with apical plasma membrane as the droplets are secreted 
from the cell. However, the accumulation of lipid within the cells causes 
secondary structural damage to both cells and alveoli, potentially suggesting 
other more indirect inhibitory mechanisms. Therefore, we attempted to 
“rescue” the Btn1a1-/- mice by reducing the lipid-droplet size and the amount 
of lipid by feeding trans-10, cis-12 conjugated linoleic acid (CLA) in early 
lactation (Table 5.1). We reasoned that decreased lipid synthesis and droplet 
size would prevent forced secretion of large lipid droplets and maintain 
mammary structure. However, if BTN is required for milk-lipid secretion, then 
lipid droplets should still accumulate within the cells. Two groups of lactating 
mice (Btn1a1+/+ and Btn1a1-/-) were fed either a control diet containing oleic 
acid (20 g/kg), or a CLA diet, in which 6.67 g oleic acid was replaced with 
6.67g CLA from day 6 to day 10 of lactation. On day 10 of lactation, milk 
samples were collected for estimation of milk-fat content. Pup weight was 
measured from day 6 to day 10 of lactation. Mammary tissue was collected  






Table 5.1. Four different sample groups used for CLA experiment.   
 
Six mice were used for per group 
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 and processed for microscopy. 
    As predicted, The CLA diet decreased milk-lipid content (%, wt/vol) by 
40% and 30% in Btn1a1+/+ and Btn1a1-/- mice, respectively (Fig. 5.7 a). The 
growth rate of pups was measured from day 6 to day 10 of lactation. As 
expected, Btn1a1+/+ mice fed with CLA grew at 50% of the rate of Btn1a1+/+ 
mice fed the control diet (Fig. 5.7 b). Likewise, the growth of Btn1a1-/- mice 
fed with CLA was reduced by about 50% compared with Btn1a1-/- control mice 
(Fig. 5.7 b). We expected that if reduced milk-fat content can rescue the 
phenotype of Btn1a1-/- mice, pup growth rate of CLA-fed Btn1a1-/- mice might 
be similar to Btn1a1-/- control mice. However, feeding a diet containing CLA in 
Btn1a1-/- mice reduced pup growth rate by about 40%, which indicates that 
feeding CLA in Btn1a1-/- mice does not rescue the phenotype of pup’s growth 
rate (Fig. 5.7 b). To determine whether feeding CLA affects the size of intra-
cellular lipid droplets and morphology of the mammary epithelial cells, the 
mammary gland was examined by either fluorescence or DIC microscopy. 
Feeding Btn1a1+/+ mice a diet containing CLA reduced the size of lipid 
droplets compared with Btn1a1+/+ mice (Fig. 5.7 c-d, g-h). However, CLA-fed 
Btn1a1-/- mice still accumulated of large lipid droplets in the lumen and in cells. 
(Fig. 5.7 e-f, i-j). Thus, CLA reduced the milk-fat content of Btn1a1+/+ and 
Btn1a1-/- mice, and this reduction was accompanied by a decrease in the size 
of both intra-cellular and secreted lipid droplets in Btn1a1+/+ mice. However, 
lipid droplets still accumulated in Btn1a1-/- mice fed CLA. Hence, reduction of 
milk-fat synthesis and lipid droplet size does not rescue the lactation  
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Fig. 5.7. Reducing fat content does not rescue the phenotype of 
Btn1a1-/- mice. (a-j) Two groups of lactating mice (Btn1a1+/+ and Btn1a1-/-) 
were fed either a control diet containing oleic acid (20 g/kg), or a CLA diet, 
in which 6.67 g/kg oleic acid was replaced with 6.67 g/kg CLA from day 6 
to day 10 of lactation. (a) Milk samples were collected on day 10 of 
lactation and milk lipid percentage (vol/vol) was estimated by crematocrit. 
(72) (b) Pup weight was measured from day 6 to day 10 of lactation. (c-f) 
Mammary tissue sections from (c, d) day 10 lactating Btn1a1+/+, and (e, f) 
Btn1a1-/- mice fed (c, e) without or (d, f) with CLA in the diet were stained 
with nile red for lipid droplets (red), WGA-Alexa 633 stain for apical 
plasma membrane (blue-green), DAPI stain for nuclei (blue). White 
arrowheads, intracellular lipid droplets. Bar, 50 µm. (g-j) Lactating 
mammary tissues were fixed simultaneously with 2.5% (w/v) 
glutaraldehyde and 2% (w/v) OsO4 and embedded in Epon. Sections (1 2 
µm) were observed directly by differential interference microscopy. (g) 
Btn1a1+/+ mice, (h) CLA-fed Btn1a1+/+ mice, (i) Btn1a1-/- mice, (j) CLA-fed 
Btn1a1-/- mice. Black arrow, intracellular lipid droplets. (Collaboration with 
Dr. A. K. G. Kadegowda) 
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phenotype of Btn1a1-/- mice, thus suggesting that BTN may play a direct role 
in milk-lipid secretion. 
 
5.6. Loss of BTN causes apoptosis in the lactating mammary gland 
As shown above, the loss of BTN causes accumulation of XOR in 
mammary epithelial cells and degeneracy in the apical plasma membrane. 
We therefore tested the possibility that apoptosis is induced in Btn1a1-/- mice, 
because of either accumulation of large lipid droplets or increased XOR levels. 
Day-10 lactating mammary glands from Btn1a1+/+ and Btn1a1-/- mice were 
examined by the TUNEL assay, and compared with day 3 involuting 
mammary glands as positive controls. There was no evidence of apoptosis in 
wild-type controls (Fig. 5.8 a-b, g). However, about 10% of the mammary 
epithelial cells in the Btn1a1-/- mice were apoptotic (Fig. 5.8 c-d, g), which is 
similar to cells in glands at day 2 of involution (Fig. 5.8 e, f, g). To confirm 
these data, the level of cleaved caspase-3 was examined by 
immunofluorescence microscopy. There was no evidence of cleaved 
caspase-3 in Btn1a1+/+ mice in agreement with the TUNEL assay. (Fig. 5.8 h, 
i). However, about half of the mammary epithelial cells were positive for 
cleaved caspase-3 (Fig. 5.8 j, k). Thus, the data from TUNEL and cleaved 
caspase-3 assays indicate that loss of BTN causes apoptosis in the lactating 
mammary gland.  
 
5.7. Accumulation of large lipid droplets does not cause cell apoptosis 
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Fig. 5.8. Loss of BTN causes apoptosis in the lactating mammary gland. 
(a-f) Tissue sections from Btn1a1+/+, Btn1a1-/-, mice at day 10 of lactation and 
Btn1a1+/+ mice at day 2 of involution were analyzed by the TUNEL assay to 
identify apoptotic cells. Tissue sections were fixed in 4% paraformaldehyde, 
and prepared as described in the manufacture’s manual (In situ Cell Death 
Dectection Kit, Fluorescein; Roche). (a, b) Btn1a1+/+ at day 10 lactation, (c, d) 
Btn1a1-/- at day 10 lactation, (e, f) Btn1a1+/+ mice at day 2 of involution. (a, c, 
e), TUNEL assay; (b, d, f) merged images with DAPI, blue (nuclei). Bars, 10 
µm. (g) Quantification of data from 3 mice (1,000 cells/mouse). (h-k) 
Mammary tissue at day 10 of lactation was fixed as described in the legend to 
Fig. 4.6 and cut into 10 µm frozen sections. (h, i) Btn1a1+/+, and (j, k) Btn1a1-/- 
mice. Sections were incubated with specific antibody to mouse cleaved 
caspase-3, followed by goat anti-(rabbit IgG-Alexa568) as secondary 
detecting agent. (h, j), cleaved caspase-3; (i, k), merged images with DAPI, 
blue (nuclei); WGA-Alexa 633 stain for apical plasma membrane, green. AL, 
aveolar lumen; white arrowheads, positive signal for TUNEL and cleaved 
caspase-3. Bars, 20 µm. 
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    As shown above, over-expression of B30.2 domain acted as a dominant 
negative inhibitor, and caused accumulation of large lipid droplets. To test the 
possibility that over-expression of the B30.2 domain induces apoptosis in the 
lactating mammary glands of wild-type mice, the level of cleaved caspase-3 in 
mammary glands expressing either B30.2+EGFP or B30.2 10+EGFP was 
examined by immunofluorescence microscopy. Day 3 involuting mammary 
glands were used as positive controls (Fig. 5.9 i-k). As expected, there was 
no evidence of cleaved caspase-3 in cells expressing B30.2 10+EGFP (Fig. 
5.9 a-d). In addition, only 0.4% of cells expressing B30.2+EGFP were positive 
with antibody to cleaved caspase-3 (Fig. 5.9 e-h).  Thus, induction of 
apoptosis is a secondary effect, most likely caused by the accumulation of 
large lipid droplets in the cytoplasm, which damages cell structure and 
triggers apoptotic signaling cascades.  
In summary, the results in this chapter show that BTN modulates the 
amount of soluble XOR in mammary epithelial cells during lactation, and that 
interaction between the two proteins is most likely required for the accretion 
and/or secretion of milk-lipid droplets.  
 




Fig. 5.9. Accumulation of large lipid droplets does not cause cell 
apoptosis. (a-h) Mammary tissue expressing B30.2 10+EGFP and 
B30.2+EGFP, as described in Fig 5.6, were cut into 10 µm frozen sections. 
(a-d) B30.2 10+EGFP, (e-h) B30.2+EGFP, and (i-k) day 3 involuting 
mammary gland. Sections were incubated with specific antibody to mouse 
cleaved caspase-3, followed by goat-anti(rabbit IgG)-Alexa633 as secondary 
detecting agent. (a) B30.2 10+EGFP, (e) B30.2+EGFP, (b, f, i) nile red, (c, g, 
j) cleaved caspase-3, (d, h, k) merged images with DAPI, blue. AL, alveolar 
lumen; white arrow head, positive signal for cleaved caspase-3 (n=3). Bars, 
50 µm. 
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Chapter 6: Discussion  
 
Our objective was to investigate the potential functions of BTN and XOR 
in the mammary gland and in the secretion of lipid droplets during lactation. 
Preliminary evidence suggested that XOR binds to the cytoplasmic domain of 
mouse BTN in an in vitro binding assay (80, 81). Furthermore, BTN and XOR 
are the most abundant MFGM proteins in most species (6, 21, 23, 34, 82), 
and Btn1a1-/- and Xdh+/- mice have a similar lactation phenotype, so we 
hypothesized that BTN and XOR may bind to each other in vivo and function 
as a complex required for milk-lipid secretion during lactation. In this context, 
several major findings from this work are especially pertinent:-  
 
(1) We showed that the cytoplasmic domain of BTN self-associates, 
probably via the stem region, which is predicted to comprise a short coiled-
coil domain (55, 83) and that the cytoplasmic domain of BTN binds to XOR in 
vitro and in vivo with relatively high affinity. Furthermore, we identified the 
B30.2 domain of BTN as the region that binds to XOR in a pH- and salt-
sensitive manner. Binding was independent of species; bovine or mouse XOR 
bound to the B30.2 domain of mouse, cow, or human BTN1A1. However, 
binding was not detected between XOR and the closely related paralogs, 
BTN2A1 and BTN3A1, or to the B30.2 domain of the unrelated RoRet (TRIM 
38) protein even though the B30.2 domains are very similar to the B30.2 
domain of BTN1A1. In vitro bead binding assays showed that bXOR binds to 
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the B30.2 domain of BTN with a monomeric binding ratio of 1:1, which is in 
agreement with the SPR data. These data are consistent with binding ratios 
for the B30.2 domain-containing proteins, GUSTAVUS and TRIM21, with their 
ligands (61, 62, 84, 85). Because bXOR is present as a homodimer in nature, 
presumably two B30.2 domains bind to one native XOR molecule. Thus, the 
binding specificity, stoichiometry, abundance and high levels of expression in 
the mammary gland suggest that BTN and XOR have specific functional roles 
in lactation. 
 
The B30.2 domain is a conserved region of approx. 170 amino acids 
associated with several protein families including the BTN and TRIM families 
(83, 86), and the B30.2 domains have been identified in at least 86 human 
genes (83). Based on available 3D structural data, the B30.2 domain is 
assumed to function as a universal protein binding module (61, 62, 84, 85). 
The structure of the B30.2 domain comprises a conserved highly distorted 
core β-sandwich which is connected by variable loops (61, 85). In the 
available 3D structures, ligand binds to the B30.2 domains via the variable 
loops either by hydrogen bonding or hydrophobic interactions (61, 85). 
Comparison of the linear sequences of the B30.2 domain of human BTN1A1 
with other family members (BTN2A1, BTN2A2, BTN2A3, BTN3A1, BTN3A2, 
and BTN3A3) shows that the most similar regions are the β-strands and that 
the loop regions are the most variable, suggesting that independent binding 
motifs are associated with the loops. The interaction of BTN with XOR shares 
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several common features with the binding characteristics of other B30.2 
domain-containing proteins with their respective ligands. Thus, the 
dissociation constant (KD) for the binding of BTN to XOR (27 nM in 20mM 
NaCl) is similar to those for GUSTAVUS (40 nM in 150mM NaCl) (84), and 
TRIM 21 (37 nM in 50 mM NaCl) (85), and in all cases, lower KD values 
(higher affinities) are associated with lower salt concentrations (79, 84, 85). 
However, because of the presumed discontinuous binding motifs of the B30.2 
domain in the linear sequence, it is not possible to predict which residues in 
BTN are responsible for binding to XOR. Resolution of these structural issues 
will require analysis by x-ray crystallography. 
 
(2) In vivo localization of BTN and XOR in the mammary gland revealed 
that BTN exclusively localizes in the apical plasma membrane, and that XOR 
is enriched at the same site. However, XOR freely diffuses in the cytoplasm in 
the absence of BTN in Btn1a1-/- mice, which suggests that BTN recruits XOR 
to the apical plasma membrane in wild-type mice. XOR was not detected on 
the surface of lipid droplets in either cultured cell lines or in lactating 
mammary tissue. Ablation of BTN gene expression in Btn1a1-/- mice 
dramatically increased the amount of XOR protein compared with wild-type 
mice, probably because XOR loses its binding partner protein, BTN, in the 
apical plasma membrane, and XOR cannot be secreted by the regular milk-
lipid secretory mechanism. However, BTN may also regulate the amount of 
XOR by transcriptional or post-transcriptional mechanisms as the amount of 
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XOR mRNA is increased in Btn1a1-/- mice compared with wild-type mice, and 
over-expression of BTN in cultured cells reduces the amount of XOR protein. 
These data suggest that BTN negatively regulates the amount of XOR in cells 
(mRNA and protein) as well as serving as a membrane anchor that binds 
directly to XOR.   
 
(3) Over-expression of cytosolic B30.2 domain acts as a dominant 
negative inhibitor, which induces a similar phenotype to that of Btn1a1-/- mice, 
i.e., the accumulation of large lipid droplets in the cytoplasm. The most facile 
explanation for this is that over-expression of the B30.2 domain inhibits the 
interaction between XOR and BTN in the apical plasma membrane, and thus 
inhibits milk-lipid secretion. These results are also consistent with data 
showing that XOR in the apical plasma membrane diffuses into the cytoplasm 
during milk stasis, at the time that large lipid droplets accumulate in the cells 
and lumen (23). However, during milk stasis, BTN remains in the apical 
plasma membrane, when XOR redistributes to the cytoplasm (23) potentially 
suggesting that milk stasis disrupts the binding between BTN and XOR by 
some unknown mechanism. One possibility is that the two proteins dissociate 
during stasis because the pH of the cytoplasm drops, and as we have shown, 
XOR does not bind to BTN below pH 6.0 (Fig. 3. 13 a).  
 
As discussed in the introduction, three models have been proposed to 
explain how BTN and XOR may function in lipid secretion (6, 23, 43, 56, 69). 
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Mather and Keenan have suggested that BTN, as a transmembrane protein, 
binds to XOR. This interaction is required for the formation of the outer 
envelope of the MFGM and expulsion of the lipid droplets into the lumen (43, 
56). In the process of lipid-droplet secretion, the lipid droplet remains a 
constant distance of about 10-20 nm from the outer apical membrane bilayer, 
which suggests that a protein coat including cytoplasmic XOR between the 
lipid droplets and outer apical membrane is responsible for secretion of the 
droplets (6). However, this model did not clarify where XOR is located, either 
on the lipid droplet surface, the apical plasma membrane, or sandwiched 
between both places. In an alternative model, McManaman et. al. have 
proposed that XOR is sandwiched between BTN in the apical plasma 
membrane and adipophilin (ADPH) on the surface of lipid droplet and is 
stabilized by disulfide bonds (23). In a radically different model, Robenek et. 
al. have suggested that milk-lipid secretion is regulated entirely by 
interactions between BTN molecules localized in both the apical plasma 
membrane and the surface of intracellular lipid droplets (69). Thus, each 
model gives rise to a set of predictions :- 
 
models Predictions 
Mather and Keenan 
(6, 43, 56) 
- BTN forms oligomers by self-association  
- BTN localizes exclusively in the apical plasma membrane  
- Cytoplasmic XOR binds to either the surface of intracellular 
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lipid droplets or the apical plasma membrane  
McManaman et. al. 
(23) 
- Both BTN and XOR localize in the apical plasma membrane 
- Either BTN or XOR bind to ADPH 
Robenek et. al. (69) - BTN localizes in both the apical plasma membrane and on  
cytoplasmic lipid droplets and does not bind to XOR 
All models - BTN should be immobile in the plane of the lipid bilayer 
(Fig. 6.1) 
 
Our results reveal that BTN exclusively localizes in the apical plasma 
membrane, and XOR locates in the cytoplasm, but is enriched in the apical 
plasma membrane. In addition, XOR does not bind to the surface of lipid 
droplets in lactating mammary gland or on lipid droplets in cultured cells. 
Furthermore, XOR freely diffuses in the cytoplasm, and accumulates in the 
absence of BTN. Thus, BTN/XOR complexes localize to the apical plasma 
membrane, presumably because BTN functions as a binding scaffold for XOR 
as predicted by Mather and Keenan (6, 43, 56) and McManaman et. al. (23). 
However, the model suggested by Robenek et. al. (69) is not consistent with 
these data. Neither is Robenek’s model consistent with our inability to detect 
BTN on intracellular lipid droplets, in either cultured cells or lactating 
mammary tissue.  
 
In all proposed models, BTN should not be mobile in the bilayer 
membrane of MFGM (Fig. 6.1). However, BTN was freely mobile in the  






Fig. 6.1. Predictions of mobility of BTN on the MFGM from three 
proposed models. (a) Interactions between BTN/XOR complexes and other 
proteins or molecules on the surface of lipid droplet may inhibit the mobility of 
BTN in the bilayer membrane of MFGM (6, 43, 56). (b) Interactions between 
BTN/XOR complexes and ADPH on the surface of lipid droplet reduce the 
mobility of BTN in the bilayer membrane of MFGM (23). (c) Interactions 
between BTN molecules, localized to both the apical membrane and the 
surface of lipid droplets, prevent BTN from moving in the bilayer membrane of 
MFGM (69).  
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bilayer of droplets evenly coated with membrane (“continuous”) with diffusion 
coefficients of the same order as BTN in the plasma membrane of HC 11 
cells. This suggests that BTN/XOR complexes are not anchored to proteins or 
molecules on the surface of lipid droplets in MFGM (Fig. 6.2). The difference 
in the mobility of mBTN-EGFP in “continuous” and “condensed” regions (Fig. 
4.15) is almost certainly a reflection of the structural changes that occur to the 
MFGM after secretion (4, 38, 78). Immediately after secretion, the bilayer is 
continuous around droplets, but during storage in the gland, the membrane 
condenses into continents and islands, and the protein coat thickens between 
the bilayer and the surface of the droplets. The observation that mBTN-EGFP 
is freely mobile in droplets with a continuous membrane is important, because 
these droplets are freshly secreted, and have not undergone any structural 
change. All three models predict that mBTN-EGFP should be immobile, even 
in these nascent lipid droplets. Thus, the FRAP data are not consistent with 
any of the proposed models.  
 
One possibility is that as in the models of Mather and Keenan (6, 43, 56), 
and McManaman et. al. (23), BTN binds to XOR in the apical plasma 
membrane (Fig. 6.3 a, b), and the complexes function in lipid droplet 
secretion. The complexes interact with proteins or molecules on the surface 
of lipid droplets (possibly ADPH) (Fig. 6.3 c) (23), and the lipid droplets are 
secreted into the lumen (Fig. 6.3 d). After secretion, proteins or molecules on 
the lipid droplet surface dissociate, and BTN/XOR complexes become freely  





Fig. 6.2. Mobility of BTN in milk-lipid droplets and in the plasma 
membrane of HC 11 cells. BTN was freely mobile in the bilayer of the MFGM, 
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Fig. 6.3. Working model for the function of BTN/XOR complexes in lipid 
droplet secretion. (a) BTN self-associates and, (b) binds to XOR in the 
apical plasma membrane. (c, d) BTN/XOR complexes bind to proteins or 
molecules on the surface of lipid droplets, and lipid droplets are secreted into 
the lumen. (e) After secretion, the complex of BTN and XOR disengages from 
the droplet and is freely mobile in the bilayer membrane.  
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mobile (Fig. 6.3 e). Interference in the interaction between BTN and XOR, 
e.g., in knock-out mouse strains (56, 63) and after over-expression of the 
B30.2 domain (Fig. 5.6), causes the accumulation of lipid droplets, and XOR 
accumulates in the cytoplasm (Figs. 4.9, 5.3). 
 
Interestingly, the loss of BTN caused cell apoptosis in lactating mammary 
gland. In appropriate physiological contexts, XOR, either as a dehydrogenase 
or an oxidase can generate ROS, including H2O2 and superoxide radical, 
which may act on downstream targets and regulate gene expression (87). 
Stress activated p56 MAP kinase induces gene expression of XOR, following 
the increase of XOR-derived ROS, and induces cell apoptosis (72, 73, 87). 
Since the accumulation of XOR causes cell death, the cells have to regulate 
the amount of XOR at sub-apoptotic levels. Consistently, XOR levels 
dramatically increase and apoptosis is induced in Btn1a1-/- mice (Fig. 5.8).  
 
Therefore, this raises the possibility that the primary function of BTN is to 
maintain mammary secretory cells in a fully differentiated state either as a 
regulator of XOR levels or as part of a signaling complex with XOR. If this 
were the case, then interference of XOR binding to BTN by over-expression 
of the B30.2 domain should induce apoptosis; first, and then only secondarily 
cause the accumulation of large lipid droplets in the cytoplasm. However, 
over-expression of cytosolic B30.2 domain induced the accumulation of large 
lipid droplets, and evidence of apoptosis was minimal (Fig. 5.9). Thus, cell 
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apoptosis in the BTN knock-out mouse appears to be a secondary effect 
caused by the accumulation of large lipid droplets and consequent structural 
damage when lipid secretion is inhibited. Elevated levels of XOR and ROS 
may also contribute to cell damage. Further experiments will be required to 
explain how the loss of BTN induces cell apoptosis in lactating mammary 
gland.  
 
In summary, the results, presented in this thesis, show that BTN binds to 
XOR with high affinity through the B30.2 domain, and that interaction between 
the two proteins in vivo is essential for the regulated accretion and/or 
secretion of lipid droplets from mammary cells during lactation.  
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